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ABSTRACT 
 
Design and Optimization of a Blood Vessel Mimic Bioreactor System for the Evaluation 
of Intravascular Devices in Simple and Complex Vessel Geometries 
by 
Sara M. Leifer 
 
Coronary artery disease affects millions of people and the ability to detect and 
treat the disease is advancing at a rapid rate. As a result, the development of intravascular 
technologies is the focus of many medical device manufacturers. Specifically, coronary 
stent implantation is being performed in an increasing number of patients and a number 
of new stent designs have been introduced to the market, resulting in the need for 
improved preclinical testing methods. An in vitro tissue engineered “blood vessel mimic” 
(BVM) system has previously been established and its feasibility for the initial testing of 
newly emerging intravascular technology has been demonstrated. There are limitations 
that exist with this original design, however, and the focus of this thesis was to both 
improve and expand upon the original model. Therefore, research was conducted based 
on two specific aims. The first aim was to develop a more ideal BVM system to 
accommodate a wider range of stent lengths and diameters, while allowing for easy graft 
insertion and seal-ability. The second aim was to develop next generation BVM systems, 
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focused on future needs and technology, such as long, angulated and bifurcated 
geometries.   
The work described in this thesis demonstrates that a BVM chamber can be 
created which has the advantages of easy graft insertion and seal-ability, as well as the 
ability to accommodate varying sizes of vessel scaffolds, all while maintaining the needs 
of a tissue engineering bioreactor system. The next generation BVM systems presented 
demonstrate that the BVM concept can be expanded to meet the needs of long, angulated 
and bifurcated geometries. Overall, the work in this thesis describes the design and 
optimization of an in vitro blood vessel mimic bioreactor system for the evaluation of 
intravascular devices, specifically coronary stents, in simple and complex vessel 
geometries. 
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1. INTRODUCTION 
Overview 
Coronary stent implantation is being performed in a large number of patients with 
a wide spectrum of clinical and lesion characteristics. From single and multiple vessel 
disease to bifurcated, angulated and long lesions, the variation and complexity of 
coronary artery disease and the advanced capabilities to detect and determine the extent 
and severity has led to an increased interest in intravascular device innovation (Zhu, et al. 
2008; Kini 2006). A variety of stent designs currently exist and continuous efforts are 
being made to improve both stent design and placement procedures (Kandzari, Tcheng 
and Zidar 2002; Kraitzer, Kloog and Zilberman 2008). Smaller delivery catheters and 
advanced delivery systems are also being introduced and have allowed the treatment of 
coronary artery disease and stent placement to become less invasive and easier on both 
the patient and physician (Yamasaki, et al. 2008; Takeshita, et al. 2008).  
With the transition from open heart surgery to balloon angioplasty and stent 
placement, minimally invasive procedures have become the most often used technique 
for treating many cardiovascular diseases (American Heart Association 2008), which in 
turn has lead to a high demand for preclinical assessments of new intravascular devices 
(Kandzari, Tcheng and Zidar 2002; Cardinal, et al. 2006). The explosive growth of 
coronary stenting has fueled a surge in the number and types of coronary stents and 
delivery systems being designed and introduced to the market. Specifically in the area of 
coronary stents, a wide range of stent materials, coatings, drugs, and configurations 
currently exist, with future developments accelerating at a rapid pace (Kraitzer, Kloog 
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and Zilberman 2008). Some of the most exciting advances can be seen in new stents 
designed specifically to treat bifurcation lesions, an area that has been very challenging 
for physicians, and new delivery systems which can deploy long or multiple stents at one 
time in order to better treat patients with long lesions or lesions in multiple vessels 
(Ikeno, Buchbinder and Yeung 2007; Stella, et al. 2008). This surge in stent technology 
has resulted in the need for new and advanced preclinical testing methods that provide 
medical device manufacturers and researchers with the ability to quickly evaluate tissue 
response to new and novel stent designs and stenting techniques.  
Coronary stents are constantly evolving devices that possess great potential, but 
each innovation and each new design that is developed must be fully evaluated before 
clinical applications are possible. Through the creation of an in vitro tissue engineered 
blood vessel construct, previously developed and called a “blood vessel mimic” (BVM), 
a model system can be established for the initial testing of newly emerging intravascular 
technology (Cardinal, et al. 2006).  The goal of this thesis is to not only expand upon the 
original BVM model, but to develop new and innovative models for the evaluation of 
devices in more complex geometries such as bifurcations, long and angulated vessels. 
The following introduction will provide the background and foundation on which 
this thesis is based. A review of coronary artery disease will be given followed by current 
diagnosis and treatment procedures. Coronary stents will be discussed in detailed, 
outlining the materials utilized, shapes, configurations, coatings and drugs used in their 
design. Other intravascular devices, delivery systems and technologies will also be 
addressed along with an overview of intravascular device preclinical testing methods and 
the BVM system specifically. The introduction will conclude with a summary of the 
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specific aims for this thesis, which will lead into the individual chapters and the models, 
experiments and studies that were built and performed. 
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Coronary Artery Disease 
Pathology 
In order to understand why intravascular technologies, specifically stents, have 
become the treatment of choice for many cardiovascular diseases, and why the medical 
community has focused so much attention on creating and testing intravascular devices to 
treat these diseases, one must appreciate the history and prevalence of the disease itself. 
Coronary artery disease (CAD), also known as coronary heart disease (CHD), is the 
number one killer of both men and women in the United States, affecting an estimated 16 
million people (American Heart Association 2008). In 2008 alone, the direct and indirect 
cost of treating CAD is estimated at $156.4 billion (American Heart Association 2008), 
making it the primary focus of many medical device manufacturers.  
The coronary arteries are small blood vessels that run along the surface of the 
heart and carry blood which supplies oxygen and nutrients to the heart muscle. The 
anatomical characteristics of coronary arteries vary considerably, ranging from straight 
simple geometries to extremely angulated bends and curves as well as bifurcations and 
long lesions (Ellis, et al. 1990; Zhu, et al. 2008; Smith, et al. 2001). Depending on the 
individual, the anatomical structure of the coronary arteries can include all or some of the 
characteristics identified above.  
Coronary artery disease can be described as atherosclerosis of the coronary 
arteries (Falk 2006; Noll 1998). Atherosclerosis occurs when the coronary arteries 
become narrowed or blocked by fatty deposits called plaque, restricting blood flow to the 
heart (Deconinck, et al. 2008). A healthy artery and an artery affected by atherosclerosis 
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are illustrated below in Figure 1.1. Without adequate blood, the heart becomes starved of 
oxygen and vital nutrients it needs to work properly. If left untreated coronary artery 
disease leads to chest pain, heart attack, heart failure and ultimately death (American 
Heart Association 2008). Therefore, action must be taken to reopen the narrowed vessels 
and restore blood flow. 
 
Figure 1.1- Atherosclerosis of the coronary arteries. Plaque accumulation on the artery 
wall results in restricted blood flow to the heart. 
 
(Permission granted to reprint image from the National Heart, Lung, and Blood Institute 
as a part of the National Institutes of Health and the U.S. Department of Health and 
Human Services; see Appendix G) 
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For many years, the process of atherosclerosis has been viewed simply as the 
accumulation
 
of lipids within the artery wall, however it is now understood that 
atherosclerosis is a complex inflammatory disease (Libby, Ridker and Maseri 2002; Ross 
1999; Noll 1998) involving endothelial cells (EC), smooth muscle cells (SMC), T-
lymphocytes, B-lymphocytes, monocytes, leukocytes and macrophages (Stoll and 
Bendszus 2006; Falk 2006). This new insight into the role of inflammation in the 
development of atherosclerosis has initiated important new areas of research in the 
treatment of coronary artery disease, most notably in the area of pharmaceuticals 
(Deconinck, et al. 2008). As will be discussed in detail, the use of pharmaceuticals on the 
surface of stents in an attempt to prevent or slow the progression of atherosclerosis is a 
recent technology and an area that is still undergoing research and in need of preclinical 
testing options. 
 
Diagnosis 
Coronary artery disease develops slowly, often without any signs or symptoms 
prior to a heart attack. However, there are a number of symptoms that can help diagnosis 
CAD and lead to proper treatment (American Heart Association 2008). The most 
common symptom of coronary artery disease is chest pain, also known as angina 
pectoris, or simply angina (Khan 2005; Crawford 2002). Angina results from the heart 
not getting enough blood and oxygen and is described as chest discomfort, heaviness, 
tightness, pressure, aching, burning, numbness, fullness, or squeezing. It is most often felt 
in the chest, but may also be felt in the shoulders, arms, neck, back or jaw. Shortness of 
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breath is a second symptom and is most often experienced during physical activity. Due 
to long-term lack of blood and oxygen, the heart becomes weak and is unable to pump 
blood throughout the body. Other less common symptoms of CAD include heart 
palpitations, irregular or rapid heartbeat, weakness, dizziness, nausea, and sweating. 
Whatever the symptom, diagnosis is the first step to treatment. 
Diagnosis of coronary artery disease begins with a complete review of medical 
and family history and a thorough physical examination (Crawford 2002). Although both 
these methods can predict the likelihood of an individual’s chance of having the disease a 
diagnostic test must be performed in order to verify the diagnosis. Often the first 
diagnostic tests chosen are an electrocardiogram (ECG or EKG) or echocardiogram 
(ECHO), since these tests are relatively low cost, simple, and non-invasive, providing fast 
information about the function of the heart. Stress tests, nuclear imaging, computerized 
tomography (CT) scans, positron emission tomography (PET) scans, magnetic resonance 
imaging (MRI) and other non-invasive diagnostic tests may also be performed, with 
varying degrees of imaging and informational capabilities. Currently, however, one of the 
most often used diagnostic tests and the reference against which all other diagnostic 
imaging tests are compared is the coronary angiogram, providing a direct image of the 
coronary arteries themselves (Budoff, et al. 2008; Sun and Jiang 2006). Coronary 
angiography is a minimally invasive imaging procedure in which a catheter is guided into 
the coronary arteries, a process often referred to as cardiac catheterization, dye is 
injected, and x-ray images are taken as the contrast material moves through the heart’s 
chambers, valves and major vessels. The resulting images are used to identify sites of 
narrowing or blockage in the coronary arteries and provide a visual picture of the location 
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and severity of coronary artery disease. Coronary angiography is illustrated below in 
Figure 1.2.   
 
Figure 1.2- Coronary angiography. A catheter is guided into the coronary arteries, dye is 
injected, and x-ray images are taken as the contrast material moves through the heart. 
 
(Permission granted to reprint image from the National Heart, Lung, and Blood Institute 
as a part of the National Institutes of Health and the U.S. Department of Health and 
Human Services; see Appendix G) 
 
Using angiography alone, however, allows only a limited quantitative analysis of 
the vessel lumen blockage from the silhouette image obtained; and although angiography 
reveals artery narrowing, it cannot differentiate between the vessel layers or identify the 
presence of plaque on the artery walls (Kern, et al. 2006; Wahle, et al. 2006). Therefore, 
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more advanced imaging techniques are often performed to supply additional information 
about the coronary arteries that angiography alone cannot provide.  
Intravascular ultrasound (IVUS) is an imaging procedure that can be performed 
simultaneously with coronary angiography in order to obtain detailed images of the walls 
of the coronary arteries. During IVUS a miniature sound-probe is positioned on the tip of 
a coronary catheter. The catheter is threaded through the coronary arteries and using 
high-frequency sound waves detailed images of the inside walls of the arteries are 
created. These images show cross-sections of the lumen revealing the layered structure of 
the vascular wall and provide information about the composition of the lesions including 
plaque shape and size (Cardinal, et al. 2006; Schoenhagen and Nissen 2002). 
No matter what technique is used, the goal of coronary imaging is to identify the 
location, characteristics, number and severity of lesions present in a patient diagnosed 
with coronary artery disease. Treatment decisions are based on these findings and 
specific treatment options are available for a number of lesion characteristics. Depending 
on the number, severity and location of the blockages found during the diagnostic 
procedure, the physician can recommend the appropriate treatment.  
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Treatment of Coronary Artery Disease 
Treatment of coronary artery disease can include lifestyle changes, medications, 
and medical procedures. The goal of each treatment is to relieve symptoms and reverse or 
slow the progression of the disease. Depending on the severity of the disease, a 
combination of treatments may be chosen. Although the focus of this thesis is on 
interventional medical procedures and intravascular devices, it is important to realize that 
if CAD is caught early enough interventional procedures or surgery may not be needed 
which is the best scenario for both the patient and physician. 
 
Lifestyle Changes and Medication 
Simple lifestyle changes can often help prevent or control CAD and for some 
individuals these changes may be the only treatment needed. It is hard to determine 
which controllable risk factors are most important but, in general, high cholesterol, 
cigarette smoking, excess weight, sedentary lifestyle, high blood pressure, and diabetes 
seem to be the most significant (American Heart Association 2008; Crawford 2002). 
Therefore, diet changes, avoiding tobacco products, exercise, and weight loss can often 
reduce these risk factors and control the onset and development of CAD.  
For some individuals, however, lifestyle changes may not be enough and 
medication may be prescribed. A number of medications are currently used, each with the 
goal of either treating the risk factors associated with CAD or treating the effects of the 
disease. Aspirin, a blood thinner, is recommended for almost everyone who has CAD, to 
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help reduce the risk of having a heart attack (Hayden, et al. 2002). Other medications 
include: anti-platelet agents and anticoagulants, which prevent the formation of blood 
clots and thin the blood; statins, which help lower cholesterol; nitrates and ACE 
inhibitors, which dilate the arteries and make it easier for blood to flow; beta-blockers 
and calcium channel blockers, which slow the heart rate and reduce blood pressure 
(Zoghbi, Dorfman and Iskandrian 2008). Unfortunately, when medications and lifestyle 
changes are not able to control symptoms or the narrowing progresses to a point that the 
heart muscle is at risk for damage, interventional procedures or surgery may be required. 
 
Coronary Artery Bypass Grafting 
A number of surgical procedures and interventional therapies have been 
developed over the past several decades to treat coronary artery disease, each with the 
goal of quickly and safely restoring blood flow to the heart. Coronary artery bypass graft 
surgery (CABG) was developed as a treatment for CAD in the late 1960’s and is still a 
frequently used technique today (American Heart Association 2008). In this procedure a 
healthy vein or artery is removed from the patient's body and used to bypass the coronary 
blockage (Khan 2005; Mullany 2003). The saphenous vein, internal mammary artery and 
radial artery are used most often, however when no healthy segment can be found within 
the patient’s body a synthetic graft material, such as expanded polytetrafluoroethylene 
(ePTFE), can also be utilized (Weyand, et al. 1999).  
During CABG the patient's chest is surgically opened and the harvested artery or 
vein is connected between the aorta and a healthy area of the heart in order to provide a 
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pathway for the blood to flow around the site of the damaged and narrowed tissue. An 
illustration of CABG is shown below in Figure 1.3.  
 
Figure 1.3- Coronary artery bypass grafting. A healthy vein or artery is connected 
between the aorta and a healthy area of the heart in order to bypass the coronary blockage 
and provide a pathway for blood to flow. 
 
(Permission granted to reprint image from the American Heart Association/American 
Stroke Association; see Appendix G) 
 
For many years, CABG had been considered the standard of care for treating 
CAD in patients at moderate to high risk of a heart attack (Hamm, et al. 1994). In many 
cases CABG is still the best choice of treatment. However, CABG can be a highly 
invasive procedure that is generally associated with long recovery times and hospital 
stays, as well as high cost (American Heart Association 2008; Mullany 2003). For many 
patients open heart surgeries, such as CABG, are not well tolerated and lead to 
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complications that are amplified by the heart’s weakened condition. Thus less invasive 
methods to treat CAD have been developed. 
 
Balloon Angioplasty 
Percutaneous coronary intervention (PCI) is a minimally invasive procedure used 
to treat patients with diseased coronary arteries. The initial innovation was balloon 
angioplasty, originally referred to as percutaneous transluminal coronary 
angioplasty (PTCA). The first balloon angioplasty was performed in 1977 by the Swiss 
physician Andreas Gruentzig (King and Meier 2000; Gruentzig 1978) and the basic 
technique is still used today. During balloon angioplasty a physician inserts a flexible 
catheter with a balloon tip into the patient’s vascular system, most often through the 
femoral artery at the groin, and maneuvers the catheter through the vascular system into 
the coronary arteries. At the site of the coronary lesion or blockage the balloon is inflated, 
compressing the plaque and stretching the artery wall, creating a wider channel and 
restoring blood flow to the heart. Balloon angioplasty is illustrated in Figure 1.4 below. 
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Figure 1.4- Balloon angioplasty. A flexible catheter with a balloon tip is maneuvered into 
the coronary arteries and inflated, compressing the plaque and stretching the artery wall 
restoring blood flow to the heart. 
 
(Permission granted to reprint image from the National Heart, Lung, and Blood Institute 
as a part of the National Institutes of Health and the U.S. Department of Health and 
Human Services; see Appendix G) 
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Coronary angioplasty provides physicians with a simple, minimally invasive 
method of opening a blocked artery without having to open the patient’s chest. This 
therapy has been widely adopted by physicians because it results in shorter hospital and 
recovery times compared to CABG and is well tolerated by most patients (American 
Heart Association 2008). However, while providing advantages over CABG, the long-
term effectiveness of balloon angioplasty is limited by restenosis, or re-narrowing of the 
artery. Restenosis is observed to occur due to two primary causes: the elastic recoil of the 
artery wall, its shrinkage back to its original size, and neointimal proliferation, the 
formation of scar tissue (Kraitzer, Kloog and Zilberman 2008; Deconinck, et al. 2008). 
This statement is an oversimplification of the process of restenosis, and restenosis will be 
discussed in detail in the following paragraphs, but for now it is important to note these 
two key observations as they are part of the motivation for the following advancements in 
treatment. 
 
Stenting 
One of most significant innovations in percutaneous coronary intervention, and 
that which is still evolving today, was the introduction of the stent in the late 1980’s 
(Waksman 2002; King and Meier 2000). Stents are tube shaped scaffolds, typically metal 
or polymer, which are used to physically hold the artery wall open and address the first 
primary cause of restenosis (Kraitzer, Kloog and Zilberman 2008; Kandzari, Tcheng and 
Zidar 2002). In an attempt to prevent elastic recoil of the artery wall stents were 
incorporated into the balloon angioplasty procedure in the early 1990’s. It is noteworthy 
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to mention, however, that the stenting of peripheral arteries had already been 
experimented with by Charles Dotter in the 1960’s who hypothesized that the use of 
stents in coronary arteries was also possible (King and Meier 2000; Dotter 1969). It 
should also be noted that in this section only a basic definition and description of stent 
design is addressed. Coronary stents will be discussed in detail in subsequent sections.  
During a percutaneous coronary interventional stenting procedure, a stent 
mounted on a balloon catheter is delivered to the lesion, or site of narrowing and 
blockage. The balloon is inflated expanding the stent, compressing the plaque and 
stretching the artery wall. The balloon catheter is then removed, leaving the stent behind 
to hold the vessel open, restoring blood flow to the heart. Stent placement is illustrated 
below in Figure 1.5.  
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Figure 1.5- Stent placement. A stent is mounted on a balloon catheter and maneuvered 
into the coronary arteries. The balloon is inflated compressing the plaque, expanding the 
stent and restoring blood flow to the heart. 
 
 (Permission granted to reprint image from the National Heart, Lung, and Blood Institute 
as a part of the National Institutes of Health and the U.S. Department of Health and 
Human Services; see Appendix G) 
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Bare Metal Stents 
In 1986, Jacques Puel and Ulrich Sigwart inserted the first bare metal stent into a 
human coronary artery (King and Meier 2000; Sigwart, et al. 1987). Bare metal stents 
(BMS) are coil, mesh or slotted tubes consisting of interconnected struts that are inserted 
inside the narrowed artery and expanded to hold it open. Stents significantly lowered the 
occurrence of restenosis by preventing elastic recoil of the artery wall and quickly 
replaced the use of balloon angioplasty as the primary interventional therapy for CAD 
(Waksman 2002; King and Meier 2000).  
In 1994 the first bare metal stents, Palmaz-Schatz and Gianturco-Roubin, were 
approved for use in the United States, and over the next decade, several generations of 
bare metal stents were developed. By early 2000, stenting was performed in over 80% of 
all PCI procedures reducing the restenosis rate to 15-20% (Holmes, et al. 2002; Waksman 
2002; Kandzari, Tcheng and Zidar 2002). Previously, restenosis rates following balloon 
angioplasty had been seen in 30-40% of patients (Silverman 2006; Waksman 2002) and 
often required re-intervention by physicians. Unfortunately, despite their widespread use, 
bare metal stents are plagued by the occurrence of in-stent restenosis, re-narrowing of the 
artery around the stent, with patients showing clinical evidence within the first 3-9 
months after implantation (Holmes, et al. 2002). In-stent restenosis around an implanted 
stent is illustrated in Figure 1.6 below. 
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Figure 1.6- In-stent restenosis. Re-narrowing of the artery around the stent. 
 
 (Permission granted to reprint image from the National Heart, Lung, and Blood Institute 
as a part of the National Institutes of Health and the U.S. Department of Health and 
Human Services; see Appendix G) 
 
Restenosis 
Restenosis is defined as the arterial healing response after injury incurred during 
coronary angioplasty (Lowe, Oesterle and Khachigian 2002; Indolfi, et al. 2003). In-stent 
restenosis (ISR) is defined as the arterial healing response due to injury incurred during 
coronary angioplasty and the presence a stent. Both restenosis and in-stent restenosis are 
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the result of a complex series of biological events in response to the initial injury of the 
vessel caused by balloon expansion and the presence of a permanent stent implant 
(Lewis, Tolhurst and Stratford 2002). 
  The process of restenosis involves vessel elastic recoil, negative remodeling, 
thrombus, smooth muscle cell proliferation, and excessive extracellular matrix production 
(Weintraub 2007). Neointimal formation, also known as neointimal proliferation, is one 
of the main mechanisms of restenosis and composed mainly of proliferating smooth 
muscle cells and extracellular matrix formation (Lowe, Oesterle and Khachigian 2002). 
In addition, inflammatory responses, foreign body reactions, and thrombogenesis occur in 
the tissue surrounding the struts of the stent and contribute to in-stent restenosis 
(Karoussos, et al. 2002). In-stent restenosis is a major clinical problem associated with 
stenting. Therefore, many efforts are being made to reduce or eliminate its occurrence.  
In recent years, drug eluting, coated and bioabsorbable stents have been 
introduced into interventional cardiology as a possible solution to the problem of in-stent 
restenosis. Researchers and medical device manufacturers are continuously testing a 
variety of drugs that are known to interrupt the biological processes that cause restenosis 
(Deconinck, et al. 2008; Kraitzer, Kloog and Zilberman 2008). Stent coatings can 
optimize the surface properties of metallic stents and serve as a vehicle for local drug 
delivery (Hara, et al. 2006). Biodegradable materials can be absorbed by the body, 
allowing a stent to act as a scaffold for a period of time and then slowly disappear once it 
is no longer needed (Mani, et al. 2007). As a result the evolution of the stent has moved 
away from being a purely mechanical object placed within the artery. With 
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pharmacologic and material advances, stents have become active devices that interact 
with their environment in complex ways.   
 
Drug Eluting Stents 
A recent innovation in percutaneous coronary intervention is the development of 
drug eluting stents (DES). Drug eluting stents address the second basic cause of 
restenosis by attempting to prevent or slow neointimal proliferation and the formation of 
scar tissue at the lesion site (Kraitzer, Kloog and Zilberman 2008; Waksman 2002; Lowe, 
Oesterle and Khachigian 2002). A drug eluting stent is a device that releases a single or 
multiple bioactive agents into the bloodstream that affect the tissue adjacent to the stent. 
The drugs used inhibit cell growth and proliferation and this advancement has resulted in 
improved patient outcomes due to reduced in-stent restenosis (Popma, et al. 2007). The 
specific drugs used to prevent restenosis and their incorporation into stent design will be 
discussed in detail in the following sections. 
In 2001, drug eluting stents (DES) were introduced into percutaneous coronary 
interventional procedures as a strategy to minimize in-stent restenosis due to neointimal 
proliferation (Kraitzer, Kloog and Zilberman 2008; Deconinck, et al. 2008). In the data 
gathered so far drug eluting stents have been extremely successful in reducing in-stent 
restenosis rates from 15-20% to single digits (Holmes, et al. 2002; Waksman 2002; 
Kandzari, Tcheng and Zidar 2002). At present, 90% of all stents placed in the United 
States are drug eluting (Popma, et al. 2007). One disadvantage, however, is the 
development of late in-stent restenosis and thrombosis, which occur after the drug has 
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been completely eluted and is no longer present in the coronary stent (Deconinck, et al. 
2008; Waksman 2007). 
 
Bioabsorbable Stents 
Despite the development and progression of bare metal and drug eluting stents, 
many concerns still remain regarding their permanent nature and influence on restenosis 
(Waksman 2007; Sharkawi, et al. 2007). Thus, bioabsorbable stents have emerged as an 
alternative to permanent metallic stents. Bioabsorbable stents, also described as 
biodegradable or bioresorbable, are constructed of metallic or polymer materials that 
degrade over time into substances that can be slowly absorbed by the body (Ormiston, et 
al. 2008; Erbel, et al. 2007). The specific materials used to create biodegradable stents 
will be discussed in the following sections. Bioabsorbable stents perform much like other 
coronary stents except that they are made of biodegradable materials that can be absorbed 
by the body, allowing them to initially act as supportive scaffolds while slowly 
disappearing as the vessel heals. The promise behind their technology lies in the fact that 
they provide a short term vessel scaffold, which can also be used for local drug delivery, 
and are then absorbed by the body avoiding the long term negative effects of permanent 
metallic stents such as in-stent restenosis and thrombosis. Currently biodegradable stents 
are not approved for clinical use in the United States (Ormiston, et al. 2008), however, 
clinical trials and research into their development are ongoing and release is expected in 
the near future. 
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Complex Lesions 
Many stents in the market today are designed and indicated for use in simple, 
straight, short lesions (Fournier, et al. 2005). However, in clinical practice coronary 
arteries are not straight and uniform. They run along the surface of the heart and are 
curved, bent, and angulated (Smith, et al. 2001). As a result, coronary stent implantation 
is being performed in an increasing number of patients with complex lesion 
characteristics including long, angulated and bifurcated lesions. 
Coronary lesions are often extremely long in length and treatment can require 
multiple overlapping stents (Ruchin, et al. 2008). Therefore, new interlocking stent 
designs, such as the Custom NX(R) DES System manufactured by XTENT, Inc., are 
exploring the possibility of deploying stents up to 60 mm in total length (Stella, et al. 
2008). It has also been observed that plaque accumulation is related to vessel curvature, 
with plaque accumulating more rapidly in angulated vessels where wall shear stress is 
low (Wahle, et al. 2006; Zhu, et al. 2008). Therefore, stents are most often placed in 
curved positions within the coronary arteries and remain in a bent position throughout 
their lifetime (Fournier, et al. 2005; Smith, et al. 2001). Many coronary stents, such as the 
MULTI-LINK manufactured by Abbott Vascular, CYPHER
®
 manufactured by Cordis, 
and TAXUS
®
 manufactured by Boston Scientific, claim superior flexibility and 
conformity which allow the stent to mold to the natural contours of the vessel wall 
(Serruys and Gershlick 2005; Rieu, et al. 2003). Consequently, accommodation of 
complex bends and geometries is being taken into greater consideration in overall stent 
design. 
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A coronary bifurcation lesion is defined as a narrowing involving both the main 
vessel and a significant side branch (Louvard, et al. 2008). Bifurcation lesions account for 
15-18% of all coronary lesions and represent one of the most complex coronary lesions to 
treat since the lumen of both the main vessel and side branch are affected and require 
treatment (Sukhija, Mehta and Sachdeva 2008). As described by the American College of 
Cardiology/American Heart Association (ACC/AHA) Guidelines for Percutaneous 
Coronary Intervention a coronary bifurcation occurs when one main vessel branches out 
into two smaller vessels, one being the continuation of the main vessel, and the other 
referred to as the side branch (Smith, et al. 2001). Recent advances have allowed 
physicians to treat bifurcation lesions, where both the main vessel and side branch need 
to be restored.  
Many techniques, with the use of single or multiple stents, have been developed 
to treat bifurcation lesions (Sukhija, Mehta and Sachdeva 2008; Iakovou, Ge and 
Colombo 2005). The simplest approach is to stent the main vessel and dilate the side 
branch through the stent struts. A second approach is to use multiple stents and can be 
accomplished through a number of different techniques. V-stenting involves the delivery 
and implantation of two stents, one in each bifurcation branch. The simultaneous kissing 
technique is similar to V-stenting in that two stents are implanted, one in each branch, 
with the difference being that the two stents touch and extend into the main branch. 
Crush, T-stenting and modified T-stenting techniques require two stents to be positioned 
perpendicular to each other, and while the techniques vary, the resulting stent 
configurations are identical. Y-stenting involves the delivery and implantation of three 
stents, one in each bifurcation branch and one in the main branch. Finally, the skirt 
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technique involves the delivery and implantation of one, two or three stents with the 
bottom half of the stent dilated to a larger diameter than the top. The bifurcation stenting 
techniques described are illustrated below in Figure 1.7.  
 
Figure 1.7- Bifurcation stenting techniques. V-stenting (a), simultaneous kissing (b), 
crush (c), T-stenting and modified T-stenting (d), Y-stenting (e) and skirt (f). 
 
(Permission granted to reprint image from Iakovou, Ge and Colombo 2005 published in 
Journal of the American College of Cardiology by Elsevier Limited.; see Appendix G) 
 
Most recently, novel stents and delivery systems such as AXXESS™ 
manufactured by Devax, Inc., PETAL™ manufactured by Boston Scientific, and 
MULTI-LINK Frontier manufactured by Abbott Vascular have been developed 
specifically to treat bifurcation lesions (Grube, et al. 2007; Ikeno, Buchbinder and Yeung 
2007; Lefèvre, et al. 2005). These stents have the potential to provide physicians with a 
method to treat complex bifurcation lesions, resulting in better procedural outcomes and 
a) b) c) 
d) e) f) 
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overcoming some of the technical difficulties associated with treating these complex 
lesions. 
In summary, the variation and complexity of coronary artery disease and the 
advanced capabilities to detect and determine the extent and severity of coronary lesions 
has led to an increased interest in intravascular device innovation (Kini 2006). With the 
development of drug eluting and bioabsorbable stents, new drugs and materials are being 
introduced at an extremely rapid pace (Kraitzer, Kloog and Zilberman 2008). Each new 
drug and material must be evaluated for biocompatibility and tissue response and the 
competitive nature of biotechnology has the medical community searching for testing 
methods and procedures that provide rapid and reliable results.  
The blood vessel mimic system has the potential to fulfill this preclinical testing 
need (Cardinal, et al. 2006). Ideally the BVM system will provide a means to rapidly 
evaluate human tissue response to varying stent configurations, materials, drugs and 
coatings as they become available. The safety of drug eluting and bioabsorbable stents, as 
well as stents designed specifically to treat complex lesions, is still an area of active 
research (Popma, et al. 2007). However, one thing remains clear- as the understanding of 
stent and tissue interactions continue to increase, the need to quickly evaluate new 
pharmacologic agents, configurations and materials will grow, and the need for a model 
system such as a BVM will be critical for preclinical device testing. 
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Intravascular Technology 
Coronary Stents 
The types and construction of coronary stents is an area of active research and 
stents are constantly undergoing evolution in terms of the materials utilized, geometrical 
configurations, sizes, and coatings (Sangiorg, et al. 2007; Hara, et al. 2006; Kandzari, 
Tcheng and Zidar 2002). Stents have evolved from simple coil and slotted tubes to 
complex configurations with active coatings and advanced features. The current BVM 
system is a means of evaluating tissue response to varying stent surfaces, coatings, and 
drugs as well as an evaluation of the physical stents themselves (Cardinal, et al. 2006). 
The BVM system is designed to test a variety of stent lengths and diameters with varying 
configurations and coatings, and knowledge of stent design is fundamental for 
understanding the needs of the system in order to physiologically mimic coronary arteries 
and induce representative cell response. Therefore, it is necessary to understand the 
general design and features of stents available in the market today. 
 
Mechanism of Expansion 
Stents can be divided according to their mechanism of expansion into two main 
categories: balloon-expandable and self-expanding (Kraitzer, Kloog and Zilberman 2008; 
Morton, Crossman and Gunn 2004). Balloon-expandable stents are made from materials 
that can be plastically deformed through the inflation of a balloon. The stent is mounted 
on the tip of a balloon catheter and the inflation of the balloon causes the stent to expand. 
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Once the balloon is deflated the stent remains in its expanded shape inside the vessel. 
Self-expanding stents, on the other hand, are manufactured in their expanded shape, then 
compressed and constrained in a delivery system. Upon release from the delivery system 
they spring back to their manufactured shape. Both balloon-expandable stents and self-
expanding stents are readily available in the market; however, balloon-expandable stents 
are more common. A list of coronary stents and their mechanism of expansion is given in 
Table 1.1.  
 
Materials 
In order to provide effective treatment for coronary artery disease, the ideal stent 
material must be flexible, fatigue resistant, expandable, corrosion resistant, biocompatible 
and visible under standard medical procedures (Poncin and Proft 2003). Currently the 
most widely used material for coronary stents is stainless steel, typically 316L (Mani, et 
al. 2007; Sangiorg, et al. 2007; Hara, et al. 2006). Stainless steel is both biocompatible 
and corrosion resistant. In its fully annealed condition, stainless steel is easily deformable 
and the standard material for balloon-expandable stents. In its full-hard condition it can 
also exhibit enough elasticity for some self-expanding stent designs. 
Although stainless steel is the most commonly used stent material, several other 
materials are currently used, with many more in development. A list of coronary stents 
and the material utilized for their construction is given in Table 1.1. The materials most 
commonly used by stent manufacturers today, after stainless steel, include cobalt 
chromium alloys, tantalum alloys, nitinol, and various polymers (Mani, et al. 2007; 
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Morton, Crossman and Gunn 2004). Cobalt chromium is more biocompatible than 
stainless steel and is being increasingly used by coronary stent manufacturers 
(Hagemeister, et al. 2005). Cobalt chromium alloys are similar in strength to stainless 
steel, but have the advantage of being more radiopaque, allowing for the design of thinner 
struts without compromising visibility (Kandzari, Tcheng and Zidar 2002). Nitinol, an 
alloy of nickel and titanium, is also a common material for coronary stents (Poncet 2005). 
With its shape memory technology, nitinol is most often used in self-expanding stents.   
Pure iron and magnesium alloys are two metals that are under development for 
use in bioabsorbable coronary stents (Mani, et al. 2007; Erbel, et al. 2007; Waksman 
2007; Waksman, et al. 2008). Bioabsorbable metallic stents look promising but their long 
term biocompatibility still needs to be studied since the elevated local concentration 
effects of these elements is unknown. In addition to metallic bioabsorbable stent 
materials, polymers such as poly-L-lactic acid (PLLA), polyglycolic acid (PGA), 
polylactic-co-glycolic acid (PLGA), poly-D,L-lactic acid (PDLA) and polycaprolactone 
(PCL) show potential for use in bioabsorbable stents (Ormiston, et al. 2008; Sharkawi, et 
al. 2007; Waksman 2007). Further research is required, however, in order to better 
understand the varying tissue responses to these materials. 
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Stent Name Manufacturer Type Material 
Expansion 
Mechanism 
Lesion Type 
MULTI-LINK 
VISION® 
Abbott Bare Metal Cobalt Chromium 
Balloon 
Expandable 
Small Vessel 
MULTI-LINK 
PIXEL®, ZETA®, 
ULTRA™ 
Abbott Bare Metal Stainless Steel 
Balloon 
Expandable 
Small Vessel 
Large Vessel 
MULTI-LINK 
FRONTIER 
Abbott Bare Metal Stainless Steel 
Balloon 
Expandable 
Bifurcation 
Dexamet Abbott Drug Eluting Stainless Steel 
Balloon 
Expandable 
Small Vessel 
FlexMaster Abbott Coated Stainless Steel 
Balloon 
Expandable 
Small Vessel 
TriMaxx Abbott Bare Metal 
Stainless Steel 
Tantalum 
Balloon 
Expandable 
Small Vessel 
ZoMaxx Abbott Drug Eluting 
Stainless Steel 
Tantalum 
Balloon 
Expandable 
Small Vessel 
XIENCE V Abbott Drug Eluting Cobalt Chromium 
Balloon 
Expandable 
Small Vessel 
BVS Abbott 
Bioabsorbable 
Drug Eluting 
Polylactic Acid (PLA) 
Balloon 
Expandable 
Small Vessel 
TAXUS® Express2 
Boston 
Scientific 
Drug Eluting Stainless Steel 
Balloon 
Expandable 
Small Vessel 
TAXUS® Petal™ 
Boston 
Scientific 
Drug Eluting Platinum Chromium 
Balloon 
Expandable 
Bifurcation 
Express2 
Boston 
Scientific 
Bare Metal Stainless Steel 
Balloon 
Expandable 
Small Vessel 
Liberté 
Boston 
Scientific 
Bare Metal Stainless Steel 
Balloon 
Expandable 
Small  Vessel 
Large Vessel 
PROMUS™ 
Boston 
Scientific 
Drug Eluting Cobalt Chromium 
Balloon 
Expandable 
Small Vessel 
BiodivYsio™ 
Biocompatibles 
Cardiovascular 
Drug Eluting Stainless Steel 
Balloon 
Expandable 
Small Vessel 
Whisper™ 
Bioabsorbable 
Therapeutics 
Bioabsorbable 
Drug Eluting 
Salicylic Acid 
Balloon 
Expandable 
Small Vessel 
CYPHER® Cordis Drug Eluting Stainless Steel 
Balloon 
Expandable 
Small Vessel 
AXXESS™ Devax, Inc. Drug Eluting Nitinol Self-Expanding Bifurcation 
Endeavor Medtronic Drug Eluting Cobalt Chromium 
Balloon 
Expandable 
Small Vessel 
Blazer OrbusNeich Bare Metal Cobalt Chromium 
Balloon 
Expandable 
Small Vessel 
R-Stent OrbusNeich Bare Metal Stainless Steel 
Balloon 
Expandable 
Small Vessel 
Carbostent™ 
Sorin 
Biomedica 
Coated Cobalt Chromium 
Balloon 
Expandable 
Small Vessel 
Custom NX(R) Xtent Drug Eluting Cobalt Chromium 
Balloon 
Expandable 
Small Vessel 
Table 1.1- Coronary stent type, material and mechanism of expansion. 
 
Data gathered from references cited throughout text. 
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Geometry and Configuration 
Coronary stents come in a variety of different geometrical configurations. Early 
stent designs were generally classified as either slotted tube or coil geometries (Morton, 
Crossman and Gunn 2004). Slotted tube designs were simply metal tubes in which slots 
or sections were cut out, leaving open patterns. Coiled stents, on the other hand, were 
made of wire or sheet metal fashioned into tube-like structures. Early coiled and slotted 
tube stents are shown below in Figure 1.8.  
 
Figure 1.8- Early coronary stent designs. Coiled (a) and slotted tube (b) geometries. 
 
(Permission granted to reprint image from Ruygrok 1997 published in The Asia Pacific 
Heart Journal by Elsevier Limited.; see Appendix G) 
a) 
b) 
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While slotted tube designs had excellent radial strength, they lacked flexibility; 
the opposite occurred for coil designs (Sangiorg, et al. 2007; Morton, Crossman and 
Gunn 2004). The resulting evolution of stent design gave way to the development of a 
large variety of stent geometries and configurations including coils, wire mesh, slotted 
tubes, corrugated, and interconnected rings. Currently, the majority of stents in clinical 
practice are classified as slotted tube or cellular designs which are either laser-cut from a 
metal tube or composed of interconnected wire rings (Morton, Crossman and Gunn 2004; 
Lau, et al. 2004). Common stent geometries are shown below in Figure 1.9. 
 
Figure 1.9- Current coronary stent designs. Sorin Carbostent (a), Medtronic beStent 2 (b), 
Cordis BxVelocity (c), and Boston Scientific Multilink Tetra (d). 
 
(Permission granted to reprint image from Colombo, Stankovic and Moses 2002 
published in Journal of the American College of Cardiology by Elsevier Limited.; see 
Appendix G) 
a) 
b) 
c) 
d) 
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As stated in the previous section, novel stents have been developed specifically to 
treat bifurcation lesions (Ikeno, Buchbinder and Yeung 2007). These stents have varying 
configurations including branches, holes, and other geometrical features that allow for 
stenting of both the main branch and side branch. Several of the new bifurcation stent 
designs employ an innovative Y-shaped or T-shaped geometry in order to match the 
anatomy of lesions that form at the junctions of coronary arteries. The PETAL™ 
bifurcation stent manufactured by Boston Scientific is shown below in Figure 1.10. 
 
Figure 1.10- Bifurcation stent design. PETAL™ bifurcation stent manufactured by 
Boston Scientific. 
 
(Permission granted to reprint image from Ikeno, Buchbinder and Yeung 2007 published 
in Cardiovascular Revascularization Medicine by Elsevier Limited.; see Appendix G) 
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Different stent designs yield varying tissue responses following implantation 
(Hara, et al. 2006) and reasearch concerning the relation of stent geometry, strut thickness 
and in-stent restenosis is ongoing. These design variations, as well as the desire to better 
understand the impact of stent characteristics on tissue response, result in a need for 
preclinical testing environments that support a range of stent shapes, geometries and 
configurations. 
 
Diameter and Length 
Coronary stents come in varying diameters and lengths (Kraitzer, Kloog and 
Zilberman 2008). A list of coronary stents along with their diameters and lengths is given 
in Table 1.2. The most common diameters available include: 2.00 mm, 2.25 mm 2.50 
mm, 2.75 mm, 3.00 mm, 3.50 mm, 4.00 mm, 4.50 mm and 5.00 mm. The most common 
lengths include: 8 mm, 12 mm, 13 mm, 15 mm, 18 mm, 23 mm, 28 mm, 33 mm, and 38 
mm. Some of the most recent designs, such as the Custom NX(R) DES System 
manufactured by XTENT, Inc., allow physicians to choose the appropriate stent length 
while inside the artery at the site of the lesion (Stella, et al. 2008). This variation results 
in a need for preclinical testing environments that support a range of stent sizes, ideally 
2.0-5.0 mm diameters and 8-38 mm lengths (Kandzari, Tcheng and Zidar 2002; Kraitzer, 
Kloog and Zilberman 2008), in order to fit the variations of coronary arteries observed in 
clinical practice and the stents currently available in the market.  
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Coatings 
The surface properties of coronary stents significantly influence tissue response 
(Mani, et al. 2007). For this reason, coatings are often applied to metallic stents in order 
to change their surface properties and improve biocompatibility. These modifications can 
also inhibit neointimal proliferation and thrombosis, which can in turn reduce the rate of 
restenosis (Lau, et al. 2004). A list of coronary stents and the type of coating applied is 
given in Table 1.2. 
The main advantage of a stent coating is the combination of mechanical stability 
and increased biocompatibility (Mani, et al. 2007). Coatings are a film of material bonded 
to the metallic surface of the stent, or embedded within the porous structure, and can be 
either passive or active. Passive coatings are inert and non-reactive in the body, while 
active coatings induce a biological response (Karoussos, et al. 2002). Many 
considerations must be taken into account when applying a stent coating including the 
biocompatibility, long-term effects, and material properties. In addition, it has been 
shown that stent coatings should not substantially enhance strut thickness because this 
promotes neointimal proliferation (Wieneke, et al. 2003).  
Organic coatings include both biodegradable polymers, including PLLA, PGA, 
PLGA, PDLA, and PCL as discussed previously, and non-biodegradable polymers. 
Polymer coatings have been proposed to improve the biocompatibility of metallic stents 
and to serve as a matrix for drug delivery (Karoussos, et al. 2002). Phosphorylcholine 
(PC) based polymer coatings, unlike many other polymer coatings, do not provoke 
excessive inflammatory or adverse reactions and provide a useful drug delivery platform, 
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especially for controlled release of drugs (Mani, et al. 2007; Waksman 2002). Other non-
biodegradable polymers for the potential use in controlled drug release include 
hyaluronic acid (HA), polyethylene-co-vinyl acetate (PEVA) and poly n-butyl 
methacrylate (PBMA).  
There are many inorganic coating materials which are suitable as stents coatings. 
Gold, silicon carbide, aluminum oxide and diamond-like carbon are some of the most 
common (Mani, et al. 2007). Gold is highly radiopaque and has been shown to be very 
biocompatible and significantly reduce neointimal proliferation and thrombosis. 
However, clinical studies have shown that gold coated stents increase the risk of 
restenosis (Karoussos, et al. 2002; vom Dahl, et al. 2002). Silicon carbide is a passive 
stent coating, which has been shown to decrease thrombosis and increase 
biocompatibility. Even so, silicon carbide coatings do not significantly reduce restenosis 
and do not have any known clinical advantage over other stent coatings (Hara, et al. 
2006). Porous ceramic coatings have become very promising for use as drug delivery 
platforms. The most recent development is a ceramic aluminum oxide coating with a 
unique nanoporous surface (Kang, et al. 2007; Wieneke, et al. 2003). Inorganic ceramic 
nanoporous aluminum oxide coatings have been shown to reduce neointimal proliferation 
and are specifically designed for incorporation of anti-restenosis drugs, which will be 
discussed in detail in the following sections. Lastly, carbon coated stents are coated with 
pure diamond-like carbon which is characterized by a polycrystalline structure and shown 
to improve biocompatibility (Mani, et al. 2007; Karoussos, et al. 2002). Currently, 
however, carbon coatings are not common in clinical use. 
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Drugs 
The ideal agent for incorporation into drug eluting stents should have potent anti-
restenosis effects while preserving vascular healing (Kraitzer, Kloog and Zilberman 
2008). Anti-inflammatory, anti-thrombogenic, anti-proliferative, and immunosuppressive 
agents which interfere with early stages of the cell cycle are currently used in coronary 
stent designs to prevent or slow the progress of in-stent restenosis. Each of these agents 
inhibits one or more of the biological processes involved in restenosis and have 
revolutionized the treatment of coronary artery disease (Waksman 2002). Table 1.2 
provides a list of coronary stents and the drugs incorporated into their designs. 
Paclitaxel, synthetically produced as Taxol, is a potent inhibitor of cell 
proliferation and prevents mitosis of cells during the G2-M phase of the cell cycle (Hara, 
et al. 2006). The cell cycle consists of five basic steps: mitosis (M), gap phase 1 (G1), 
dormancy (G0), synthesis (S) and gap phase 2 (G2). G2-M is the transition in the cell 
cycle from state G2, where the cell produces enough proteins to divide, to state M, where 
the cell divides into two daughter cells. Paclitaxel acts by binding to microtubules during 
the G2 phase, thus preventing mitosis and cell replication. As a result, it inhibits smooth 
muscle cell proliferation and smooth muscle cell migration and has been shown to reduce 
inflammation (Deconinck, et al. 2008). Sirolimus, also known as rapamycin, its 
analogues zotarolimus and everolimus, and ABT-578 which is a synthetic analogue of 
rapamycin, block cell cycle progression at the G1-S transition (Kraitzer, Kloog and 
Zilberman 2008). G1-S is the transition in the cell cycle between phase G1, where the 
cell increases in size while producing proteins and RNA, to phase S when DNA 
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replication occurs. As a result, it inhibits smooth muscle cell proliferation as well as T-
cell and B-cell proliferation. Sirolimus and its derivatives are also known to prevent 
smooth muscle cell migration and reduce inflammation (Deconinck, et al. 2008; Mani, et 
al. 2007). An illustration of the cell cycle is shown below in Figure 1.11 identifying the 
cell cycle transition phase inhibited by both paclitaxel and sirolimus.  
 
Figure 1.11- Cell Cycle. Sirolimus blocks cell cycle progression at the G1-S transition 
while paclitaxel prevents mitosis of cells during the G2-M transition. 
 
(Permission granted to reprint image from Hara, et al. 2006 published in Advanced Drug 
Delivery Reviews by Elsevier Limited.; see Appendix G) 
 
Other common agents for incorporation into drug eluting stents include tacrolimus 
(FK506), dexamethasone, and heparin (Deconinck, et al. 2008; Kraitzer, Kloog and 
Zilberman 2008). Tacrolimus and dexamethasone are both cellular proliferation 
inhibitors. Tacrolimus prevents the proliferation of T-cells, lymphocytes and smooth 
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muscle cells. Dexamethasone is a well established anti-inflammatory agent and inhibits 
the proliferation of fibroblasts, smooth muscle cells and macrophages. Heparin, an 
anticoagulant, reduces leukocyte and platelet adhesion and protects against stent 
thrombosis (Mani, et al. 2007; Hara, et al. 2006). It also prohibits smooth muscle cell 
migration and proliferation. 
Localized drug delivery using stents as the drug delivery platform is advantageous 
since the drug is release at the precise location and at the time of vessel injury (Kraitzer, 
Kloog and Zilberman 2008). In addition, higher local concentrations are achievable with 
little risk of system toxicity. Currently there are three different approaches to binding 
drugs to coronary stents: drug binding by means of a polymer on the stent surface, drug 
binding aided by an inorganic stent coating, or direct drug binding to the stent surface 
without coating (Acharya and Park 2006). Drugs are most often either chemically bonded 
to the surface of the stent or trapped within a polymer film or porous ceramic that allows 
controlled drug release (Kandzari, Tcheng and Zidar 2002). Drug release in 
biodegradable coatings is achieved through disintegration of the biodegradable polymer 
of the stent, while non-biodegradable coatings release drugs by allowing the drugs to 
diffuse through a porous matrix. 
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Stent Name Manufacturer Diameter (mm) Length (mm) Coating Drug 
MULTI-LINK 
VISION® 
Abbott 
2.0,2.25,2.5 
2.75,3.0,3.5,4.0 
8,12,15 
18,23,28 
None None 
MULTI-LINK 
PIXEL®, ZETA®, 
ULTRA™ 
Abbott 
2.0,2.25,2.5 
2.75,3.0,3.5 
4.0,4.5, 5.0 
8,13,15,18 
23,28,33,38 
None None 
MULTI-LINK 
FRONTIER 
Abbott 2.5,3.0,3.5,4.0 18 None None 
Dexamet Abbott 
2.0,2.25,2.5 
2.75,3.0,3.5,4.0 
7,8,10,11,15 
18,22,28 
Phosphorylcholine (PC) Dexamethasone 
FlexMaster Abbott 
2.5,2.75 
3.0,3.5,4.0 
9,12,16 
19,23,26 
None Heparin 
TriMaxx Abbott 
2.25,2.5,2.75 
3.0,3.5,4.0 
8,13,15 
18,23,28 
None None 
ZoMaxx Abbott NA NA Phosphorylcholine (PC) Zotarolimus 
XIENCE V Abbott 
2.5,2.75 
3.0,3.5,4.0 
8,12,15 
18,23,28 
Polyvinylidene Fluoride 
(PVDF) 
Hexafluoropropylene 
(HFP) 
Everolimus 
BVS Abbott NA NA None Everolimus 
TAXUS® Express2 
Boston 
Scientific 
2.5,2.75 
3.0,3.5 
8,12,16,20 
24,28,32 
Polystyrene-b-
isobutylene-b-styrene 
Paclitaxel 
TAXUS® Petal™ 
Boston 
Scientific 
NA NA 
Polystyrene-b-
isobutylene-b-styrene 
Paclitaxel 
Express2 
Boston 
Scientific 
2.5, 2.75 
8,12,16 
20,24 
None None 
Liberté 
Boston 
Scientific 
2.75,3.0,3.5 
4.0,4.5,5.0 
8,12,16,20 
24,28,32 
None None 
PROMUS™ 
Boston 
Scientific 
2.5,2.75 
3.0,3.5,4.0 
8,12,15 
18,23,28 
Polyvinylidene Fluoride 
(PVDF) 
Hexafluoropropylene 
(HFP) 
Everolimus 
BiodivYsio™ 
Biocompatibles 
Cardiovascular 
NA NA Phosphorylcholine (PC) Dexamethasone 
Whisper™ 
Bioabsorbable 
Therapeutics 
NA NA None 
Sirolimus   
Salicylic Acid 
Conor Medstent™ 
Conor 
Medsystems 
NA NA 
Polylactide-co-glycolic 
Acid (PLGA) 
Paclitaxel 
CYPHER® Cordis 
2.5,2.75 
3.0,3.5 
8,13,18 
23,28,33 
Polyethylene-co-vinyl 
Acetate (PEVA) 
Poly-n-butyl 
Methacrylate (PBMA) 
Sirolimus 
ACHIEVE™ Cook NA NA None Paclitaxel 
AXXESS™ Devax, Inc. NA NA Polylactic Acid (PLA) Biolimus A9® 
Endeavor Medtronic NA NA Phosphorylcholine (PC) Zotarolimus 
Blazer OrbusNeich 
2.5,2.75 
3.0,3.5,4.0 
9,13,15 
18,23,28,33 
None None 
R-Stent OrbusNeich 
2.5,2.75 
3.0,3.5,4.0 
9,13,15 
18,23,28,33 
None None 
Janus Carbostent™ 
Sorin 
Biomedica 
NA NA Carbon Tacrolimus 
Custom NX(R) Xtent NA 36,60 Polylactic Acid (PLA) Biolimus A9® 
Table 1.2- Coronary stent diameters, lengths, coatings and drugs. 
 
Data gathered from references cited throughout text. 
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There are many different stent coatings and drugs being researched today and 
only the most promising were addressed in this section. Those in clinical use at the 
present time are being perfected and many new and different coatings and drugs will be 
developed in the future. Tables 1.1 and 1.2 illustrate the various combinations of 
geometries, sizes, coatings, and drugs currently available in the market as well as those 
being designed for future clinical use. Many of these stents are currently undergoing 
clinical trials and are likely to be released in the near future. Others are still in the initial 
design phases and in need of a preclinical testing environment such as the BVM system. 
 
Delivery Systems 
In addition to the advancements in coronary stent design, the method of delivering 
these therapies has also improved. These improvements have made percutaneous 
coronary interventional procedures easier to perform and have reduced the amount of 
time for a single procedure. Over-the-wire delivery systems represented the first 
significant innovation in PCI procedures (Abrams, Baum and Pentecost 2006; Simpson, 
et al. 1982). Over-the-wire delivery systems allow manipulation of the guidewire 
independently from the balloon catheter. Rapid exchange, or monorail, delivery systems 
represent the next advancement and were developed to simplify the exchange of catheters 
by allowing a much shorter length of guidewire to be used. Rapid exchange delivery 
systems allow a single operator to manage both the catheter and the guidewire during a 
PCI procedure (Bonnett, et al. 2004). 
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Stent delivery and implantation in complex coronary geometries is a challenge for 
conventional delivery systems. It is often difficult to maneuver 6 French catheters, the 
current standard for most stent delivery devices, through tortuous vessel geometries 
(Saeed, Banerjee and Brilakis 2008). The French catheter scale is commonly used to 
measure the outer diameter of cylindrical medical instruments, with one French 
equivalent to 0.013 inches. As a result, a novel 4 French balloon catheter was designed 
for the treatment of a variety of coronary artery lesions and provides a less invasive 
method of treatment while improving procedural outcomes (Takeshita, et al. 2008). The 
CardioMind Sparrow™ coronary stent delivery system manufactured by CardioMind is 
another low profile delivery device consisting of a self-expanding nitinol stent loaded 
into a 0.014 inch guidewire platform with the ability to travel through tortuous 
geometries (Yamasaki, et al. 2008; Abizaid, et al. 2007).  
In addition to tortuous vessel geometries and the need for lower profile and more 
flexible delivery systems, complex coronary lesions often require high-pressure balloon 
inflation for complete stent and lumen expansion. The use of high-pressure balloon 
inflation has been associated with an increased incidence of restenosis due to injury 
caused by balloon inflation (Oesterle, et al. 1998). Therefore, novel low-pressure dilation 
balloon catheters, such as the FX miniRAIL manufactured by X Technologies, are being 
explored as a method to reduce the balloon pressure required for stent expansion in 
complex coronary lesions (Ischinger, Solar and Hitzke 2003). 
Percutaneous coronary intervention in complex coronary geometries is difficult 
and the increased complexity results in reduced success rates (Saeed, Banerjee and 
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Brilakis 2008). Therefore, novel delivery systems, smaller catheters, lower profile 
balloons and other devices have been created to overcome the challenges associated with 
tortuous anatomies. Stent delivery is an area of active research and a living model system 
for testing and evaluating these new delivery devices would be ideal for development and 
progression of the field.  
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Preclinical Device Testing 
Preclinical device testing is a crucial step in the process of developing and 
releasing new medical devices to the market. The objective of preclinical testing is to 
provide preliminary evidence of product safety and efficacy in order to support the 
initiation of human clinical trials (Wall and Shani 2008). Preclinical testing typically 
begins using models and methods that are simple and cost-effective in order to identify 
potential failures as early in the development process as possible, and then progresses to 
models with increasing complexity. Preclinical intravascular device testing is currently 
performed using laboratory models, in vitro cellular models, and in vivo animal models 
and provides critical information about cellular and tissue responses as well as device 
success. 
 
Laboratory Models 
One of the first steps in preclinical intravascular device testing involves the use of 
laboratory models. Prior to determining the cellular response to a device research must be 
performed in order to verify device functionality. Laboratory models are often used to 
physically mimic the geometry of coronary arteries and allow a large number of device 
designs to be evaluated quickly and inexpensively. For example, synthetic models in 
which vessel shaped troughs are bored through plastic blocks are often constructed for 
preclinical testing of stents in order to simulate device expansion and delivery within a 
coronary vessel (Ormiston, et al. 1999). Other models use flexible tubing to mimic the 
vascular structure of the coronary arteries and foam-like material to represent and mimic 
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the presence of a lesion (Connolley, et al. 2007). These types of synthetic model 
approaches allow stents to be deployed and evaluated in coronary geometries; however, 
no cellular lining exists to provide physiological response evaluations. 
It is important to remember that stent implantation is a mechanical intervention 
and the engineering aspects and mechanical performance of the stent design must be 
evaluated. Methods for identifying mechanical complications enable preclinical screening 
of stent designs, which reduces the amount of animal testing required and provides a 
method for evaluating new stent designs and stenting techniques prior to animal and 
human clinical trials. 
 
In Vitro Cellular Models 
Following functional and mechanical testing in a laboratory model, in vitro 
cellular models are the next step in preclinical intravascular device testing. Although a 
more complex dynamic system exists in vivo, a common preclinical evaluation method 
involves culturing endothelial cells in vitro in order to study their response to new drugs, 
materials, and devices (Cenni, et al. 1999). These cells can be maintained as two-
dimensional monolayers in flasks or dishes, or cultured in three-dimension adhered to 
scaffolds or suspended in solution (Bokhari, et al. 2007; Cheng, Lai and Kisaalita 2008; 
Cui, et al. 2007; Sun, et al. 2006). Either of these cellular models can then be exposed to 
samples of new materials or medical devices in order to assess responses such as cell 
proliferation, cell migration, and cell death. Although in vitro cell cultures do not reflect 
the complexity of a living system, they provide important insights into cellular response 
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and are critical in the effort to minimize the time and cost associated with in vivo animal 
and human studies. 
 
In Vivo Animal Models 
Currently most preclinical biocompatibility and tissue response testing is done on 
animals in outside laboratories, which is both time consuming and expensive. Animal 
studies, however, are a valuable tool and much of what is known about restenosis and the 
healing response after stent implantation has been gathered from the study of both 
healthy and atherosclerotic animal models (Touchard and Schwartz 2006; Schwartz, 
Chronos and Virmani 2004; Wieneke, et al. 1999).  
The ideal animal model for preclinical intravascular device testing should be 
readily available, inexpensive, and easy to handle. More importantly, it should closely 
mimic the human pathophysiology of neointimal proliferation and remodeling (Russell 
and Proctor 2006; Kantor, et al. 1999). Current animal models for preclinical 
intravascular device testing include mice, rats, rabbits, pigs, dogs, and primates (Russell 
and Proctor 2006; Touchard and Schwartz 2006; Schwartz, Chronos and Virmani 2004). 
 The Apo E-deficient mouse model has become the most widely used animal 
model in atherosclerosis research (Desai, Zhao and Warren 2008; Fazio and Linton 
2001). Apo E-deficient mice have been genetically altered so that they naturally develop 
high cholesterol, leading to atherosclerosis and the development of coronary lesions and 
blockages much like those found in human coronary arteries (Russell and Proctor 2006).  
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The rat carotid artery and the rabbit iliac model are the most commonly used 
animal models for testing intravascular devices targeted at preventing restenosis. Rats and 
rabbits are small and relatively inexpensive, providing a fast and reliable animal model 
for preclinical testing. One disadvantage is that rats and rabbits are highly resistant to the 
development of atherosclerosis, necessitating the use of either a high cholesterol diet or 
vessel injury to mimic coronary lesions (Schwartz, Chronos and Virmani 2004; Wieneke, 
et al. 1999). However, even healthy rat and rabbit models provide important information 
regarding the vascular healing response that occurs after device implantation.  
In addition to rats and rabbits, the pig has become a widely used species for 
assessing treatments of restenosis because its coronary anatomy and physiology are 
similar to those of humans and are susceptible to atherosclerosis, developing thick 
neointimal lesions in response to injury (Russell and Proctor 2006; Schwartz, Chronos 
and Virmani 2004). Large animas, such as dogs and primates, are also useful models but 
are not commonly used due to high cost, ethical considerations, and long life spans.  
Although preclinical animal studies are accepted as a means to predict the 
probability of device safety and effectiveness in humans, no animal model can provide 
complete insight into the human healing response following stent implantation (Wall and 
Shani 2008; Fazio and Linton 2001; Wieneke, et al. 1999). The need exists for preclinical 
testing using live human cells and tissue. Preclinical testing using human cells would 
greatly increase the medical community’s understanding of tissue response to a specific 
device prior to animal and patient testing and prior to device release. Presently, it is 
difficult to simulate device and tissue interaction and research still needs to be done to 
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fully understand tissue behavior and the in vivo interaction that occurs between device 
and tissue.  
 
Blood Vessel Mimic 
Previous work has demonstrated that a 3-dimensional in vitro tissue engineered 
blood vessel mimic (BVM) can be created and maintained in a bioreactor system to serve 
as a potentially ideal environment for coronary stent implantation and testing prior to 
animal and clinical studies (Cardinal, et al. 2006). The in vitro blood vessel mimic system 
can allow initial preclinical testing to be performed on a large number of coating 
combinations and stent configurations in order to direct animal and clinical studies 
toward the most promising devices. The major advantage of the in vitro blood vessel 
mimic system is its potential for consistent high-throughput evaluation of cellular 
response to advancing intravascular technologies. 
The in vitro blood vessel mimic design and concept is based upon existing 
techniques for tissue engineered vascular grafts and bioreactor systems. Human 
microvascular endothelial cells isolated from adipose tissue are pressure sodded onto 
tubular expanded polytetrafluoroethylene (ePTFE) scaffolds and cultivated in bioreactor 
systems under flow to form a “blood vessel mimic”. Results demonstrate that a thin, 
confluent cellular lining on the inner lumen of the ePTFE scaffold can be created in vitro. 
Stent deployment within the blood vessel mimic is also possible and after being 
cultivated in the bioreactor system for several days a thin lining of cells forms over the 
stent surface.  
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The BVM system described above (Cardinal, et al. 2006) consists of a custom 
built horizontal rectangular vessel chamber that houses an ePTFE scaffold. An individual 
BVM chamber is shown below in Figure 1.12.  Following vessel cultivation and growth 
within the chamber, stents or other intravascular technologies can be evaluated and 
tested. 
 
Figure 1.12- Individual BVM chamber. 
 
The BVM system provides an intermediate testing environment for assessing 
human cellular responses to intravascular stents in a manner that combines the 
advantages of both in vitro and in vivo approaches. The blood vessel mimic system 
utilizes human cells, which provide the potential for more predictive preclinical results 
than animal models alone can provide. It is important to note that the blood vessel mimic 
system is not a substitute or replacement for animal models. The overall goal of the BVM 
system is to provide a more relevant in vitro tissue model that can be used for the 
preclinical evaluation of new intravascular devices. 
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Summary and Aims of the Thesis 
Coronary artery disease affects millions of people and the ability to detect and 
treat the disease is advancing at a rapid rate. Intravascular device technology is the focus 
of many medical device manufacturers and with coronary stent implantation being 
performed in an increasing number of patients a number of new stent designs have been 
introduced to the market, resulting in the need for improved preclinical testing methods.  
A blood vessel mimic (BVM) system has previously been established and its 
feasibility for the initial testing of newly emerging intravascular technology has been 
demonstrated. The current BVM system has been used successfully to support the growth 
of tissue engineered in vitro blood vessel mimics, and its components and usefulness 
have been summarized. With that said, there are limitations that exist with the original 
design and the focus of this thesis is to both improve and expand upon the original model. 
The goal of this thesis is to develop a BVM system which has the advantages of 
simplicity and ease of assembly, as well as the ability to accommodate varying sizes of 
vessel scaffolds and to expand the BVM concept to an area that currently has not been 
addressed, such as long, angulated and bifurcation lesions, all while maintaining the 
needs of a tissue engineering bioreactor system.  
The general hypothesis driving this thesis project was that design changes could 
be made and new configurations implemented to the BVM system that would improve 
function and usability for preclinical device testing. In order to test this hypothesis, 
research was conducted based on two specific aims. The first aim was to develop a more 
ideal BVM system. The specific hypothesis in this case was that a BVM chamber could 
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be created to accommodate a wider range of stent lengths and diameters, while allowing 
for easy graft insertion and seal-ability. The second aim was to develop next generation 
BVM systems, focused on future needs and technology. The hypothesis in this case was 
that with emerging technology the ability to test stents specifically for bifurcation lesions, 
as well as in long and angulated vessels, will be needed and is possible within the BVM 
system. The prototypes developed and the findings from constructed models are 
presented and discussed in the following chapters. 
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2. INITIAL DESIGN OF AN IDEAL BVM 
Introduction 
A bioreactor is a system in which conditions are closely controlled in order to 
induce a specific behavior in living cells or tissue (Martin, Wendt and Heberer 2004; 
Korossis, et al. 2005). Design and construction of bioreactors are very important in tissue 
engineering research, because they directly provide the in vitro environment for tissue 
growth (Chen and Hu 2006). A bioreactor attempts to mimic physiological conditions in 
order to maintain and encourage cell growth. Bioreactor technologies intended for tissue 
engineering can be used to grow functional cells and tissues for transplantation and for 
controlled in vitro studies. It is the second application on which this thesis is focused: the 
use of bioreactors for controlled in vitro studies.  
The primary objectives of tissue engineering bioreactors are to establish spatially 
uniform cell distributions on three dimensional scaffolds, to maintain desired 
concentrations of gases and nutrients in the culture medium, and to expose developing 
tissue to appropriate physical stimuli (Korossis, et al. 2005). The requirements of a 
bioreactor vary depending on the dimensions, complexity, and physiological environment 
of the tissue to be engineered. Most importantly, however, the bioreactor has to be able to 
operate over sustained periods of time under aseptic conditions so that cells are able to 
grow and function (Chen and Hu 2006). The overall goal is to create a system that 
reliably and reproducibly supports the growth of functional living tissue (Martin, Wendt 
and Heberer 2004; Ratcliffe and Niklason 2002).  
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The previously developed, original BVM system (Cardinal, et al. 2006) consists 
of a custom built horizontal rectangular vessel chamber with three ports: a luminal inlet, 
luminal outlet, and extra luminal outlet. Both outlets lead to a two-port media reservoir, 
with external side clamps controlling the flow path. The scaffold is attached to two 
barbed fittings which are inserted into the luminal inlet and luminal outlet ports located 
within the vessel chamber. Adjustments to length are made by pulling or pushing the 
tubing in or out of the chamber. The top of the chamber is optically clear allowing for 
easy visualization of the scaffold, media and stent placement. The chamber itself is sealed 
using rubber o-rings and clamped together by tightening four screws. Flow is created 
using a peristaltic pump, with media entering the luminal inlet and exiting through the 
luminal outlet and extra luminal outlet. The system can be sterilized using ethylene oxide 
(EO) gas.  Although advantages of this original system exist, it would be desirable to 
improve upon this design in order to create a more ideal BVM system. 
One common disadvantage among many bioreactor systems is the amount of 
difficulty experienced when installing or removing scaffolds (Singh, et al. 2007), and this 
is true for the original BVM system. This is often a challenge in itself as sterility needs to 
be maintained at all times. Easy handling and assembly also lowers the risk of 
contamination (Fisher, Mikos and Bronzino 2007). A more user friendly design is one of 
the primary needs of the BVM system. Easy scaffold insertion, without the need for 
bending or twisting, along with a method to quickly and simply seal the vessel chamber 
without the need for tools, would greatly improve the usability of the BVM system.  
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A second need for the BVM system is the ability to accommodate a wider range 
of stent sizes. As discussed in detail in the introduction to this thesis, stents range in 
shape and size, and thus a BVM system would ideally accommodate 2.0-5.0 mm 
diameters and 8-38 mm lengths (Kandzari, Tcheng and Zidar 2002; Kraitzer, Kloog and 
Zilberman 2008), in order to fit the variations of coronary arteries observed in clinical 
practice and the stents currently available in the market.  
In addition, ideally the BVM system would be easy to manufacture and utilize 
materials and components that are readily available and cost-effective so that scale-up is 
possible (Fisher, Mikos and Bronzino 2007; Martin, Wendt and Heberer 2004). Other 
considerations in design of the BVM system include sterilization method, incubator 
configuration, aseptic change of culture media, tissue monitoring, and reproducibility 
(Fisher, Mikos and Bronzino 2007). The aim of the work in this chapter was to improve 
upon the original BVM system by developing a new, more ideal design, with the 
hypothesis being that a simpler, easier to use and more variable design could be created 
and implemented for preclinical device testing. The specific design criteria to be met are 
summarized below: 
 An overall user friendly design so that assembly is simple and straightforward 
 Easy scaffold insertion and removal without the need for bending or twisting 
 Easy to seal leak-proof chamber for quick and sterile assembly 
 Adjustable scaffold length and diameter for greater testing variability 
 Sterilizable by ethylene oxide (EO) gas 
 Optically clear chamber for easy visibility of scaffold, media and stent placement 
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 Easy scale-up so that multiple chambers can be configured in the incubator 
 Low cost 
 Easy to manufacture without the need for adhesive or special tooling 
 Use of materials and components that are readily available and easy to obtain 
 Use of biocompatible materials so that cells are able to grow and function 
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Initial Design Models and Concepts 
Initial design ideas and concepts were drawn and modeled. These designs were 
free flowing ideas based only on the known limitations, needs and design criteria to be 
met for the new BVM system. Ideas were recorded or drawn in a lab notebook over a 
time period of several days before any evaluations were made. Drawings were then 
turned into basic 3D models using SolidWorks (SolidWorks Student Design Kit 2008) for 
visualization and comparison. These designs were recorded without regard to feasibility 
of design, availability of components, cost or any other idea limiting factors. It should be 
noted that only the luminal inlet and luminal outlet were modeled, since location of the 
extra luminal outlet was not critical to the basic design. In addition, tubing attachment, 
connections and fittings were not addressed in these initial designs as the goal was only 
to develop a basic model. The five initial design ideas that were developed are modeled 
and described below. 
Prior to the building of any prototypes the initial design ideas and concepts were 
reviewed and evaluated based on the following criteria: user friendly design, seal-ability, 
availability of materials and components, adjustability, and overall cost. Each model was 
examined to first determine if it could actually be built and function, and if so, whether 
the components were readily available or easy to create. Finally, even if the design could 
be built and parts were available, consideration was taken into design complexity, 
manufacturability and overall cost. The evaluation of each initial design is presented 
below following the design model and description. 
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Initial Design 1 
Description: The first initial design idea consisted of clear plastic rectangular top 
and bottom sections that meet at the center and snap together. The two sections could be 
separate pieces or possibly held together by a hinge. The entire midsection would contain 
a rubber o-ring and when snapped together the top and bottom sections would create a 
leak-proof seal. Two centered holes would be made on opposite ends of the box, resulting 
in half circle indentations on both the top and bottom sections. The two holes on either 
end of the box would also contain a rubber seal and when snapped together they would 
encompass the scaffold and tubing and create a tight leak-proof seal around the tubing. 
During set-up, the scaffold and tubing would be placed along the center of the bottom 
section, within the half circle indentations, prior to placement of the top section. Initial 
Design 1 is modeled in Figures 2.1 and 2.2 below.  
 
Figure 2.1- Exploded 3D model of Initial Design 1. An exploded view shows the overall 
design concept with the top and bottom sections separated. The scaffold and tubing is set 
across the bottom section and placed within the half circle indentations. 
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Figure 2.2- Assembled 3D model of Initial Design 1. An assembled view shows the 
overall design concept with the top and bottom sections snapped and sealed together. The 
scaffold and tubing is encompassed between the top and bottom sections, with the half 
circle indentations sealed around the tubing. 
 
Evaluation: The biggest advantage of this design is that the snapping top and 
bottom sections would be easy to assemble and use. This design would be easy to open, 
close and put together. The box design would be easy to configure in an incubator and is 
stackable. Scaffold placement would be simple, as it would lie across the bottom section 
within the half circle indentations. The scaffold and tubing could be set in place without 
the need for stretching or bending. Clear plastic would allow for visibility and could be 
sterilized using ethylene oxide (EO) gas. The scaffold length would be somewhat 
variable, but limited by the chamber length. The limiting factor of this design is seal-
ability. The entire midsection must seal together and the half circle indentations must 
create a leak-proof seal around the tubing. Manufacture of this type of seal design would 
be complicated, expensive and require adhesive and custom made parts. The major 
disadvantage of this design was that no container could be found with this configuration 
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and creating a functioning seal would be challenging. The overall evaluation of Initial 
Design 1 is summarized below: 
 User friendly design: Yes- chamber would be easy to assemble and scaffold 
would be easy to insert  
 Seal-ability: Difficult- it would be hard to design and ensure a complete leak-
proof seal across the tubing and along all edges 
 Availability of materials and components: Custom- some components would need 
to be custom built and designed 
 Adjustability: Limited- longest scaffold would be limited by chamber length 
 Cost: Moderate to High- due to custom parts and complex seal design 
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Initial Design 2 
Description: The second initial design idea consisted of two clear plastic 
cylindrical sections that meet at the center and slide together, encompassing the scaffold 
and tubing.  The two sections would be separate pieces with the inside diameter of the 
larger section matching the outside diameter of the smaller section. The open ends of the 
cylindrical sections would contain rubber o-rings and when slid together the two sections 
would create a leak-proof seal. The resulting seal would function both in a stationary 
position and when the two sections are slid together or apart. Two centered holes would 
be made on opposite ends of the cylinder, with the tubing and scaffold placed within the 
center. During set-up, the scaffold would be inserted into the tubing, prior to closure of 
the two sections. Initial Design 2 is modeled in Figures 2.3 and 2.4 below. 
 
Figure 2.3- Exploded 3D model of Initial Design 2. An exploded view shows the overall 
design concept with the two cylindrical sections separated. The scaffold and tubing is 
placed within the center. 
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Figure 2.4- Assembled 3D model of Initial Design 2. An assembled view shows the 
overall design concept with the two cylindrical sections slid and sealed together. The 
scaffold and tubing is encompassed within the two cylindrical sections. 
 
Evaluation: The biggest advantage of this design is that the length of the chamber 
would be easily adjustable. The two sliding sections would allow for variable scaffold 
length with precise adjustment of chamber length depending on the scaffold size used. 
The sliding cylindrical sections would be easy to assemble and scaffold placement would 
be simple. Clear plastic would allow for visibility and could be sterilized using ethylene 
oxide (EO) gas. Again, the overall limiting factor of this design is seal-ability. This 
design would need circular o-ring seals on the cylindrical sections, and the seals would 
need to hold and remain leak-proof while sliding. Manufacture of this type of seal design 
would be complicated, expensive and most likely wear out over time due to sliding. This 
design would be difficult to build even though the materials are available. Usability is 
also a concern. A cylindrical shape would be challenging to work with and place in the 
incubator as it would roll and is not stackable. This design would also be difficult to 
configure in regards to tubing adjustability, as the tubing would also need to slide and 
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adjust as the chamber slides. The overall evaluation of Initial Design 2 is summarized 
below: 
 User friendly design: Somewhat- chamber would be easy to assemble and 
scaffold would be easy to insert, but chamber would roll on a flat surface 
 Seal-ability: Difficult- it would be hard to design and ensure a complete leak-
proof sliding seal that would not wear over time 
 Availability of materials and components: Custom- some components would need 
to be custom built and designed 
 Adjustability: High- chamber length can be easily adjusted to scaffold length 
 Cost: Moderate to High- due to custom parts and complex seal design 
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Initial Design 3 
Description: The third initial design idea consisted of a clear plastic cylindrical 
center section with clear plastic adjustable corrugated tubing on both ends. The 
corrugated tubing sections could be pushed and pulled to change the overall length of the 
chamber. The corrugated tubing would be permanently attached and sealed to the center 
section with one end completely closed. The other end of the corrugated tubing would 
have a threaded or snapping leak-proof cap to create an opening for scaffold placement. 
Two centered holes would be made, one on the closed end of the cylinder and one on the 
cap, and the tubing and scaffold would be placed through the center. During set-up, the 
scaffold would be inserted into the tubing, prior to closure of the cap. Initial Design 3 is 
modeled in Figures 2.5 and 2.6 below. 
 
Figure 2.5- Side view 3D model of Initial Design 3. A side view shows the overall design 
concept with the corrugated tubing sections attached to the center section. The scaffold 
and tubing is placed within the center. 
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Figure 2.6- Assembled 3D model of Initial Design 3. An assembled view shows the 
overall design concept with the corrugated tubing sections and center sealed together. 
The scaffold and tubing is encompassed within the chamber. 
 
Evaluation: The biggest advantage of this design is that the length of the chamber 
would be easily adjustable. The corrugated tubing could be pushed and pulled and would 
allow for variable scaffold length with precise adjustment of chamber length depending 
on the scaffold size used. The snapping cap would be easy to assemble and seal. Clear 
plastic would allow for visibility and could be sterilized using ethylene oxide (EO) gas. 
Scaffold insertion would be difficult, since access to the center can only be made from 
one end. Manufacture of this type of design would be difficult requiring adhesive when 
attaching the corrugated tubing to the center section.  In addition, corrugated tubing is 
expensive and custom lengths and configurations would be needed. The limiting factors 
for this design are scaffold insertion, manufacturability and cost. Again, usability is a 
concern. A cylindrical shape would be challenging to work with and place in the 
incubator as it would roll and is not stackable. This design would be difficult to configure 
in regards to tubing adjustability, as the tubing would need to slide and adjust as the 
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corrugated tubing is pulled or pushed. The overall evaluation of Initial Design 3 is 
summarized below: 
 User friendly design: No- chamber would be easy to assemble but scaffold 
insertion would be difficult and chamber would roll when on a flat surface 
 Seal-ability: Easy- entire chamber would be closed and only need a leak-proof 
sealing cap 
 Availability of materials and components: Custom- corrugated tubing would need 
to be custom ordered and designed 
 Adjustability: High- chamber length can be easily adjusted to scaffold length 
 Cost: High- due to corrugated tubing, adhesive, manufacturing and overall 
complex and custom design 
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Initial Design 4 
Description: The fourth initial design idea consisted of a clear plastic rectangular 
box with snap-on sealing lid. The box and lid could be separate pieces or possibly held 
together by a hinge. The box would be completely open on top, allowing for complete 
access into the chamber, and the lid would contain a rubber o-ring. When snapped 
together the lid would create a leak-proof seal against the top of the box. Two centered 
holes would be made on opposite sides in the bottom of the box, and the tubing and 
scaffold would be positioned in the middle. During set-up, the scaffold and tubing would 
be placed in the center of the bottom section, prior to placement and closure of the lid. 
Initial Design 4 is modeled in Figures 2.7 and 2.8 below. 
 
Figure 2.7- Exploded 3D model of Initial Design 4. An exploded view shows the overall 
design concept with the top and bottom sections separated. The scaffold and tubing is 
placed in the center of the bottom section. 
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Figure 2.8- Assembled 3D model of Initial Design 4. An assembled view shows the 
overall design concept with the top and bottom sections snapped and sealed together. The 
scaffold and tubing is encompassed within the box. 
 
Evaluation: The biggest advantage of this design is that the snapping lid would be 
easy to assemble, use and seal. This design would be easy to open, close and put together. 
The box design would be easy to configure in an incubator and is stackable. Scaffold 
placement would be simple, as it would be placed in the center of the bottom section. 
Clear plastic would allow for visibility and could be sterilized using ethylene oxide (EO) 
gas. Containers of this type are readily available in a number of shapes and sizes and are 
low in cost. No custom designed parts would be needed and manufacturing would be 
simple without the need for adhesive or any complex seal design. This design would be 
easy to build and materials are available. The scaffold length would be somewhat 
variable, but limited by the chamber length. The main drawback of this design is that the 
length of the chamber is not easily adjustable. The overall evaluation of Initial Design 4 
is summarized below: 
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 User friendly design: Yes- chamber would be easy to assemble and scaffold 
would be easy to insert  
 Seal-ability: Easy- only the lid would contain a sealing o-ring which would 
experience minimal wear 
 Availability of materials and components: Off the Shelf- standard shaped 
container available in many sizes with no custom parts 
 Adjustability: Limited- longest scaffold would be limited by chamber length 
 Cost: Low- materials and components are off the shelf and readily available with 
nothing custom needed 
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Initial Design 5 
Description: The final initial design idea consisted of a clear plastic cylindrical 
container with sealing snap-on lid. The cylindrical container would be open on top and 
the lid would contain a rubber o-ring seal. When snapped together the lid would create a 
leak-proof seal against the top of the cylindrical container. Two holes would be made in 
the lid. The tubing and scaffold would hang vertically from one of the holes, loop around 
in a u-shape, and exit through the second hole. Initial Design 5 is modeled in Figures 2.9 
and 2.10 below. 
 
Figure 2.9- Exploded 3D model of Initial Design 5. An exploded view shows the overall 
design concept with the top and bottom sections separated. The scaffold and tubing are 
looped into a u-shape and hang vertically from the lid. 
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Figure 2.10- Assembled 3D model of Initial Design 5. An assembled view shows the 
overall design concept with the top and bottom sections snapped and sealed together. The 
scaffold and tubing are encompassed within the cylindrical chamber. 
 
Evaluation: The biggest advantage of this design is that the snapping lid would be 
easy to assemble, use and seal. Scaffold placement would be simple, as it would hang 
from the lid. Clear plastic would allow for visibility and could be sterilized using 
ethylene oxide (EO) gas. The chamber would be easy to configure in an incubator but is 
not stackable due to the tubing being attached to the lid. Containers of this type are 
readily available in a number of shapes and sizes and are low in cost. No custom 
designed parts would be needed and manufacturing would be simple without the need for 
adhesive or any complex seal design. This design would be easy to build and materials 
are available. The scaffold length would be somewhat variable, but limited by the 
container length. In addition, the tubing length would need to be adjusted each time the 
scaffold length is changed. The key difference and possible challenge in this design is 
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that the scaffold is oriented vertically. The overall evaluation of Initial Design 5 is 
summarized below: 
 User friendly design: Yes- chamber would be easy to assemble and scaffold 
would be easy to insert  
 Seal-ability: Easy- only the lid would contain a sealing o-ring which would 
experience minimal wear 
 Availability of materials and components: Off the Shelf- standard shaped 
container available in many sizes with no custom parts 
 Adjustability: Limited- longest scaffold would be limited by chamber length 
 Cost: Low- materials and components are off the shelf and readily available with 
nothing custom needed 
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Evaluation of Initial Design Models and Concepts 
A summary of the design criteria evaluated in the previous section is given in 
Table 2.1 below. Initial designs 1 through 5 were evaluated based on user friendly design, 
seal-ability, availability of materials and components, adjustability, and overall cost. The 
results of these evaluated criteria were used when deciding what initial designs to move 
forward with and build into physical prototypes. 
 
Initial 
Design 1 
Initial 
Design 2 
Initial 
Design 3 
Initial 
Design 4 
Initial 
Design 5 
User Friendly 
Design 
Yes Somewhat No Yes Yes 
Seal-Ability Difficult Difficult Easy Easy Easy 
Availability of 
Materials and 
Components 
Custom Custom 
Very 
Custom 
Off the 
Shelf 
Off the 
Shelf 
Adjustability Limited High High Limited Limited 
Cost 
Moderate 
to High 
Moderate 
to High 
High Low Low 
Table 2.1- Evaluation of initial design ideas. The initial design ideas were evaluated 
based on the following criteria: user friendly design, seal-ability, availability of materials 
and components, adjustability, and overall cost.  
 
Ultimately the final decision on what designs to move forward with and build into 
prototypes was based on seal-ability and availability of materials and components, along 
with consideration of the other above stated criteria. The highest priority was choosing a 
design that could be easily sealed and remain leak-proof, so that sterility could be 
maintained. Seal-ability is extremely important since a sterile environment is needed for 
cell and tissue growth (Fisher, Mikos and Bronzino 2007; Chen and Hu 2006).  The next 
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consideration was choosing a design that could actually be built, utilizing materials and 
components that are readily available, since the aim of this thesis was to both design and 
build a BVM system for preclinical device testing. A design was needed that could be 
easily manufactured without the need for adhesive or custom parts. A more user friendly 
design was one of the primary needs of the BVM system and was the next consideration. 
Those designs in which scaffold placement was simple and overall usability was easy 
were given priority. Although cost was not a major deciding factor, the designs that 
utilized off the shelf components also had the advantage of being low cost. Finally, a 
more variable design with the ability to accommodate a wider range of stent sizes was the 
last consideration. In evaluating all the designs, adjustability became a minor 
consideration. Although a custom adjustable chamber would be nice, a longer scaffold 
could be easily accommodated in the other designs by simply choosing a larger container. 
Therefore, adjustability was given the least priority when choosing the designs with 
which to move forward and prototype. To summarize, the evaluated design criteria were 
given the following priorities:  
1. Seal-ability 
2. Availability of materials and components 
3. User friendly design 
4. Cost 
5. Adjustability 
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After prioritizing the above criteria and evaluating the results found in Table 2.1, 
only initial designs 3, 4 and 5 met the top design criteria of being easy to seal. 
Additionally, initial designs 4 and 5 met the second criteria utilizing materials and 
components that are easily available and off the shelf, rather than needing to be custom 
designed or ordered. Early evaluation revealed initial designs 4 and 5 as the designs with 
the most potential, meeting the top 4 out of 5 design criteria stated above.  
While searching for available materials and components, a simple solution was 
found to overcome the challenge of seal-ability and manufacturability which further 
narrowed the overall design considerations down to initial designs 4 and 5. By using a 
leak-proof plastic food container with snap-on sealable lid and built in o-ring, the basic 
chamber design was solidified and initial designs 4 and 5 were chosen to be prototyped. 
Initial designs 4 and 5 also had the advantage of being both user friendly and low cost 
designs. Figure 2.11 below shows commercially available plastic food containers with 
snap-on lids in several different shapes and sizes. 
 
Figure 2.11- Leak-proof plastic food container with snap-on sealing lid. 
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A leak-proof plastic food container was chosen for the chamber design because it 
is easy to seal, made of clear biocompatible and sterilizable plastic, low cost and 
available in local stores. Leak-proof polypropylene food containers come in a variety of 
shapes, sizes and configurations with lids that have built-in silicone o-rings. The leak-
proof food container meets the following design criteria stated in the introduction:  
 An overall user friendly design so that assembly is simple and straightforward 
 Standard container configuration with snap-on lid 
 Easy to seal leak-proof chamber for quick and sterile assembly 
 Lid has built-in silicone o-ring and latches that snap to seal 
 Sterilizable by ethylene oxide (EO) gas 
 Polypropylene and silicone can withstand EO sterilization 
 Optically clear chamber for easy visibility of scaffold, media and stent placement 
 All sides of container are see-through 
 Easy scale-up so that multiple chambers can be configured in the incubator 
 Containers are stackable and modular  
 Low cost 
 Approximately $3-10 per container, depending on size 
 Made of materials and components that are readily available and easy to obtain 
 Containers can be purchased in local stores or online 
 Made of biocompatible materials so that cells are able to grow and function 
 Polypropylene and silicone are biocompatible materials  
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Design Prototypes 
After identifying containers and identifying initial designs 4 and 5 as the best 
potential candidates, the next step was to build physical prototypes to evaluate and further 
narrow the selection to one final design. The following two prototypes were constructed 
by purchasing leak-proof plastic food containers from Linens-N-Things, fittings and 
connections from Value Plastics, Qosina, and McMaster-Carr and flexible tubing from 
Cole-Parmer. The two prototypes were assembled based on the above models of initial 
designs 4 and 5 and are shown and described below. Details on how the fittings were 
secured, specific parts used and the entire assembly process will be addressed in the 
following chapter after the final design has been chosen. The goal of this section was to 
build physical prototypes that could be held, compared, and evaluated by potential users 
in order to determine the final design. 
 
Design Prototype 1 
Description: The first prototype built was based on the model of initial design 4. 
A rectangular, clear, plastic, leak-proof food container with snap-on sealing lid was used 
for the chamber. The container used measured approximately 5" long x 3.5" wide x 2" 
deep. The lid contained a silicone o-ring seal and four snapping latches that locked to the 
bottom section securing the bottom and lid together. Two holes were made on opposite 
sides of the container and threaded luer lock to barbed connection fittings were secured 
within the holes. The scaffold was horizontally positioned between the fittings using the 
appropriate connections. Adjustment to scaffold length could be made by adding or 
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removing fittings.  Photographs of the physical prototype built are shown below in 
Figures 2.12 and 2.13. 
 
Figure 2.12- Side view of Prototype 1. A rectangular plastic leak-proof container with 
snap-on sealing lid was used for the chamber.  
 
 
Figure 2.13- Top view of Prototype 1. The scaffold was horizontally positioned within 
the chamber using the appropriate connections. 
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Design Prototype 2 
Description: The second prototype built was based on the model of initial design 
5. A tall rectangular, clear, plastic, leak-proof food container with snap-on sealing lid was 
used. The container used measured approximately 4" wide x 4" wide x 4.5" tall. The lid 
contained a silicone o-ring seal and four snapping latches that locked to the bottom 
section securing the bottom and lid together. Two holes were made in the lid of the 
container and threaded luer lock to barbed connection fittings were secured within the 
holes. The scaffold was hung vertically from the lid using the appropriate connections 
and the tubing was configured in a u-shape. Adjustment to scaffold length could be made 
by changing the opposite side tubing length. A photograph of the physical prototype built 
is shown below in Figure 2.14. 
 
Figure 2.14- Front view of Prototype 2. A rectangular plastic leak-proof container with 
snap-on sealing lid was used for the chamber. The scaffold hung vertically from the lid. 
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Evaluation of Design Prototypes 
Prototypes 1 and 2 were evaluated in comparison with the original BVM system 
and to each other based on an expanded list of key criteria. The original BVM system 
along with physical Prototypes 1 and 2 were handled and used by several individuals in 
order to evaluate overall usability and ease of scaffold insertion. Measurable criteria 
evaluated included volume, maximum scaffold length and diameter, and maximum stent 
size. Observable criteria included graft orientation, closure mechanism, need for 
assembly tools, and stack-ability. Other criteria included cost and chamber design. Table 
2.2 below summarizes the results of the compared criteria of the original BVM system, 
Prototype 1 and Prototype 2.   
 
Original BVM 
System 
Design 
Prototype 1 
Design 
Prototype 2 
Overall Usability moderate easy easy 
Scaffold Insertion difficult easy moderate 
Chamber Volume 25 ml 350 ml 700 ml 
Graft Orientation horizontal horizontal vertical 
Closure Mechanism screws locking snaps locking snaps 
Assembly tools required yes no no 
Stackable no yes no 
Max Scaffold Length 4.5 cm 5.5 cm 6 cm 
Scaffold Diameters 3-4 mm 2-6 mm 2-6 mm 
Maximum Stent Length 25 mm 35 mm 40 mm 
Stent Diameters 3-4 mm 2-6 mm 2-6 mm 
Cost moderate low low 
Chamber Design custom off the shelf off the shelf 
Table 2.2- Evaluation of design prototypes versus original BVM system. The design 
prototypes were compared to the original BVM system and evaluated based on objective, 
measurable and observable criteria. 
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Prototype 1 and Prototype 2 met all design criteria stated in the introduction. 
When compared to the original BVM system, both prototypes also had the advantage of 
being more user friendly with easier scaffold placement and utilized a simpler closure 
mechanism without the need for assembly tools. The overall usability and ease of 
scaffold insertion was evaluated by the individuals that make up the 2008 BVM Lab 
Group, after handling and using all three designs. It was observed that locking snaps 
provided a quick and simple sealing method when compared with the previous method of 
tightening screws. Also, by using rotating fittings in the prototype designs the need to 
bend, push or twist the scaffold during insertion was eliminated.  
In addition to usability characteristics, the prototypes were lower cost and 
chamber designs were non-custom and off the shelf. Maximum scaffold length and 
diameter was also greater in the prototype designs, resulting in the accommodation of a 
wider range of stent sizes. The stent sizes that could be inserted into the scaffold were 
estimated by taking the maximum scaffold length and subtracting 2 cm to take into 
account the amount of material used for attachment and the amount of non-useable area.  
As described above, Prototypes 1 and 2 have many advantages over the original 
BVM system. The next step in designing a new, more ideal BVM was to compare 
Prototypes 1 and 2 to each other. The significant difference in design between Prototype 
1 and Prototype 2 was scaffold orientation. The original BVM system utilizes a 
horizontal scaffold orientation and previous evaluation and use of a vertically oriented 
scaffold have revealed difficulties in cell sodding, with the cells tending to migrate to the 
bottom of the scaffold due to gravity (KO Cardinal, unpublished data). Therefore the 
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biggest disadvantage of Prototype 2 was the vertical scaffold orientation. Chamber 
volume was also compared and considered. Although not critical, a smaller volume is 
more advantageous since it requires less media to fill. Both prototypes were much larger 
in volume than the original BVM system, however, Prototype 2 was twice the volume of 
Prototype 1. In addition to a horizontal scaffold orientation and smaller chamber volume, 
Prototype 1 also has the advantage of being stackable when compared to Prototype 2. As 
a result of these advantages, Prototype 1 was chosen to be used for the final design. 
 
Final Design 
Based upon the previously discussed evaluation, Prototype 1 was chosen to be 
used as the final design. The following chapter will review in detail the design, 
construction and set-up of this Ideal BVM system as well as the testing performed to 
validate and verify its functionality and use. 
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3. FINAL DESIGN OF IDEAL BVM 
Introduction 
As stated in the previous chapter, design and construction of bioreactors are 
important in tissue engineering research because they directly provide the in vitro 
environment for tissue growth (Chen and Hu 2006). A bioreactor must operate over 
sustained periods of time under aseptic conditions so that cells are able to grow and 
function. The goal is to create a system that reliably and reproducibly supports the growth 
of functional living tissue (Martin, Wendt and Heberer 2004; Ratcliffe and Niklason 
2002). In the case of a Blood Vessel Mimic (BVM), the goal is to create an environment 
to cultivate tissue engineered blood vessels (TEBV) in order to serve as a living vessel 
model for preclinical device testing (Cardinal, et al. 2006). The aim of the work in the 
previous chapter was to improve upon the original BVM system by developing a new, 
more ideal design. A simpler, easier to use and more variable design was selected from 
several potential ideas and an initial physical prototype was built and modeled.  
The new Ideal BVM system developed and prototyped in the previous chapter 
consists of an off the shelf leak-proof plastic horizontal rectangular vessel chamber with a 
luminal inlet, luminal outlet and extra luminal outlet. The outlets lead to a two-port media 
reservoir, with stopcocks controlling the flow path. The scaffold is attached to two 
rotating luer fittings which are attached to the luminal inlet and luminal outlet ports 
located within the vessel chamber. Adjustments to length are made by adding or 
removing luer fittings. All sides of the chamber are optically clear allowing for easy 
visualization of the scaffold, media and stent placement. The chamber itself is sealed by a 
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built-in silicone o-ring and clamped together by closing four snapping latches. The 
system can be sterilized using ethylene oxide (EO) gas. The specific design criteria met 
by the Ideal BVM were summarized in Chapter 2 and provided the motivation for 
moving forward with this design. Therefore, the aim of the work in this chapter is to 
describe in detail the finalized design, construction and set-up of this Ideal BVM system 
and the testing performed to validate and verify its functionality and use. 
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Materials and Methods 
Ideal BVM System 
This section outlines the steps taken to build the new Ideal BVM system. The 
assembly process is described in detail and includes the specific parts used along with 
detailed illustrations. While this section provides the materials and methods for 
construction of the Ideal BVM system, a detailed list of parts and drawings, as well as 
complete step-by-step directions can also be found in Appendix B and C respectively. 
The new, Ideal BVM system was constructed as follows. 
To begin, the luminal inlet, luminal outlet and extra luminal outlet were created 
and assembled. Three 15/64" holes were drilled into the sides of a 350 ml, 5" x 4" x 2", 
semitransparent, polypropylene rectangular snap and seal leak-proof food container 
(Lock & Lock P/N HPL806). Two holes were drilled on opposite sides, one in the center 
of each face, directly across from one another. The centered hole on the left hand side 
became the luminal inlet and the centered hole on the right hand side became the luminal 
outlet. A third hole was drilled adjacent to the centered face hole on the right hand side of 
the container. This hole became the extra luminal outlet. Using a razor blade, the edges of 
the holes were cleaned of any plastic debris that resulted from the use of the drill. A soft 
black Buna-N o-ring, AS568A dash number 006, durometer 50A, 1/4" OD, 1/8" ID, 
1/16" W (McMaster-Carr P/N 2418T112) was slid onto a white nylon, female luer lug 
style panel mount connector, 1/4-28 UNF to 200 series barb, 1/8" ID tubing (Value 
Plastics P/N FTLB230-1) and threaded through one of the drilled holes with the barbed 
portion exiting the container. A second o-ring was placed over the barbed section and a 
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Female  
Luer Lug 
Panel Mount 
Lock Nut 
O-Rings 
white nylon, 1/4-28 UNF panel mount lock nut (Value Plastics P/N LNS-1) was screwed 
on tightly, pressing the o-rings against the inside and outside of the container walls, 
creating a leak-proof seal. Once securely tightened, a drop of Loctite 4011 medical grade 
adhesive (McMaster-Carr P/N 1818A4) was placed between the lock nut and the threaded 
portion of the barbed fitting to secure it in place and prevent loosening. This procedure 
was repeated for the remaining drilled holes. Figures 3.1 and 3.2 below illustrate this 
assembly procedure. 
 
Figure 3.1- Assembly of the luminal inlet and luminal outlets. Each of the three 15/64" 
holes was assembled using two o-rings, a female luer lug panel mount and a lock nut.  
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Luminal 
Outlet 
Extra Luminal 
Outlet 
Luminal 
Inlet 
 
Figure 3.2- Completed assembly of the luminal inlet and luminal outlets. The female luer 
lug panel mounts were threaded through the holes drilled in the plastic container and the 
lock nuts were tightened, pressing the o-rings against the container walls creating a seal. 
 
To complete the luminal inlet assembly a 2" piece of Tygon® silicone tubing, 
1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was inserted onto the barbed fitting 
of the luminal inlet exiting the left side of the container. A white nylon, female luer 
thread style to 200 series barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1) was 
attached to the open end of the silicone tubing attached to the luminal inlet. Finally, a 
three-way polycarbonate stopcock with two female and one male luer lock ends (Value 
Plastics P/N VPB1000079N) was attached to the female luer end on the luminal inlet 
tubing. The assembly process described is illustrated in Figures 3.3 and 3.4 below. 
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Figure 3.3- Luminal inlet tubing assembly. The luminal inlet consists of a short piece of 
silicone tubing, a female luer thread barbed fitting, and a three-way stopcock. 
 
 
Figure 3.4- Completed luminal inlet tubing assembly. 
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To complete the luminal outlet and extra luminal outlet assembly a 1" piece of 
Tygon® silicone tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was 
inserted onto the barbed fitting of the luminal outlet and a 5" piece of the same silicone 
tubing was inserted onto the barbed fitting of the extra luminal outlet, both exiting the 
right side of the container. A white nylon, male luer integral lock ring to 200 series barb, 
1/8" ID tubing (Value Plastics P/N MTLL230-1) was attached to the open end of the 
silicone tubing attached to the luminal outlet. A one-way polycarbonate stopcock with 
one female and one male luer lock end (Value Plastics P/N VP455980) was attached to 
the male luer end on the luminal outlet tubing. A white nylon, female luer thread style to 
200 series barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1) was attached to the male 
end of the one-way stopcock, and a 2" piece of Tygon® silicone tubing, 1/8" ID x 1/4" 
OD (Cole-Parmer P/N WU-95702-06) was inserted onto the barbed fitting of the female 
luer attached to the one-way stopcock.  
Next, the open ends of the silicone tubing attached to the luminal outlet and extra 
luminal outlet were attached to a white nylon, Y-connector with 200 series barbs, 1/8" ID 
tubing (Value Plastics P/N Y230-1). The attachment of the luminal outlet and extra 
luminal outlet tubing to the Y-connector created one main outlet. Finally, a 1" piece of 
Tygon® silicone tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was 
inserted onto the barbed fitting of the Y-connector and a white nylon, male luer integral 
lock ring to 200 series barb, 1/8" ID tubing (Value Plastics P/N MTLL230-1) was 
inserted into the open end of the silicone tubing attached to the Y-connector. A one-way 
polycarbonate stopcock with one female and one male luer lock end (Value Plastics P/N 
VP455980) was attached to the male luer end on the Y-connector tubing. Figure 3.5 
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provides an overall view of the assembly process, and Figures 3.6 and 3.7 provide a 
closer view of the luminal outlet and extra luminal outlet assembly. 
 
Figure 3.5- Overall view of luminal outlet and extra luminal outlet assembly. 
 
 
Figure 3.6- Detailed view of luminal outlet and extra luminal outlet assembly. The 
luminal outlet assembly consists of a one-way stopcock, while the extra luminal outlet is 
a simple tube. The luminal outlet and extra luminal outlet are both attached to a Y-
connector and meet to form one outlet ending with a one-way stopcock. 
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Figure 3.7- Completed luminal outlet and extra luminal outlet assembly. The two outlets 
meet at the Y-connector combining to form one main outlet. 
 
To complete the inside of the chamber, two male-to-male luer lock connectors, 
with one rotating collar (Qosina P/N 17644), were attached to the female luer lock 
connector ends of the luminal inlet and luminal outlet, extending into the chamber. The 
male-to-male connectors were attached so that the rotating collars extended into the 
chamber and were free to rotate. Figures 3.8 and 3.9 below illustrate this assembly 
procedure. To shorten the distance between the two ends of the male-to-male luer lock 
connectors, white nylon male luer integral lock ring to female luer thread style couplers 
(Value Plastics P/N LC34-1) can be attached prior to the attachment of the male-to-male 
luer lock connectors. The attachment of one coupler to both the luminal inlet and luminal 
outlet is illustrated in Figures 3.10 and 3.11 below and will be detailed in a later section. 
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Figure 3.8- Attachment of male-to-male luer lock connectors. Male-to-male luer lock 
connectors, with one rotating collar, were attached to the female luer lock connector end 
of the luminal inlet and luminal outlet. 
 
 
Figure 3.9- Completed attachment of male-to-male luer lock connectors. Male-to-male 
luer lock connectors were attached so that the end extending into the chamber remained 
free to rotate. 
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Figure 3.10- Addition of male-to-female luer lock couplers. Prior to the attachment of the 
male-to-male luer lock connectors, male-to-female couplers can be added to shorten the 
distance between the rotating ends. 
 
 
Figure 3.11- Attachment of male-to-female luer lock couplers. Male-to-male luer lock 
connectors were attached so that the end extending into the chamber remained free to 
rotate. 
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The final complete new Ideal BVM system, prior to scaffold insertion, is 
diagramed below in Figure 3.12. The lid is attached by closing four snapping latches and 
a built-in o-ring creates a leak-proof seal. The Ideal BVM system was part of the overall 
bioreactor configuration, which will be diagramed in a later section. 
 
Figure 3.12- Final complete new Ideal BVM system. 
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Two-Port Media Reservoir 
This section outlines the steps taken to build the two-port media reservoir for the 
new Ideal BVM system. After construction of the luminal inlet and luminal outlets of the 
Ideal BVM system it was observed that this configuration would also improve the 
function and use of the inlet and outlet ports on the media reservoir lid, allowing reservoir 
construction to be accomplished without the need for a large amount of adhesive. 
Therefore, the same basic construction used to build the Ideal BVM system luminal inlet 
and luminal outlets was applied to the two-port media reservoir. The assembly process is 
described in detail and includes the specific parts used along with detailed illustrations. 
While this section provides the materials and methods for construction of the two-port 
media reservoir, a detailed list of parts and drawings, as well as complete step-by-step 
directions can also be found in Appendix B and D respectively. 
The two-port media reservoir for the Ideal BVM system was created as follows. 
Two 15/64" holes were drilled into the lid of a BD Falcon™ 50 ml conical-bottom 
polypropylene tube (BD Biosciences P/N 352098). Using a razor blade, the edges of the 
holes were cleaned of any plastic debris that resulted from the use of the drill. Using the 
same technique described previously, a soft black Buna-N o-ring, AS568A dash number 
006, durometer 50A, 1/4" OD, 1/8" ID, 1/16" W (McMaster-Carr P/N 2418T112) was 
slid onto a white nylon, female luer lug style panel mount connector, 1/4-28 UNF to 200 
series barb, 1/8" ID tubing (Value Plastics P/N FTLB230-1) and threaded through one of 
the drilled holes with the barbed portion exiting the top of the lid. A second o-ring was 
placed over the barbed section and a white nylon, 1/4-28 UNF panel mount lock nut 
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(Value Plastics P/N LNS-1) was screwed on tightly, pressing the o-rings against the top 
and bottom of the lid, creating a leak-proof seal. Once securely tightened, a drop of 
Loctite 4011 medical grade adhesive (McMaster-Carr P/N 1818A4) was placed between 
the lock nut and the threaded portion of the barbed fitting to secure it in place and prevent 
loosening. This procedure was repeated for the second drilled hole. Next, a 1" piece of 
Tygon® silicone tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was 
attached to a white nylon, male luer integral lock ring to 200 series barb, 1/8" ID tubing 
(Value Plastics P/N MTLL230-1) and secured to one of the female luer fittings extending 
from the bottom of the lid. This port, with the attached tubing, became the outlet. The 
assembly process described is illustrated in Figures 3.13 and 3.14 below. 
 
Figure 3.13- Assembly of two-port media reservoir lid. Each of the two 15/64" holes was 
assembled using two o-rings, a female luer lug panel mount and a lock nut. A short piece 
of tubing was inserted onto a male luer lock barbed fitting and attached to the assembly. 
  
 
96 
 
Outlet Inlet 
 
Figure 3.14- Assembled two-port media reservoir. The female luer lug panel mounts were 
threaded through the drilled holes and the lock nuts were tightened, pressing the o-rings 
against the top and bottom of the lid, creating a seal. A short piece of silicone tubing was 
attached and became the outlet. 
 
To complete the two-port media reservoir two 10" pieces of Tygon® silicone 
tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) were inserted onto the 
barbed fittings of the inlet and outlet exiting the media reservoir lid. A white nylon, male 
luer integral lock ring to 200 series barb, 1/8" ID tubing (Value Plastics P/N MTLL230-
1) was attached to the open end of the silicone tubing attached to the outlet. Likewise, a 
white nylon, female luer thread style to 200 series barb, 1/8" ID tubing (Value Plastics 
P/N FTLL230-1) was attached to the open end of the silicone tubing attached to the inlet. 
Figures 3.15 and 3.16 below illustrate this assembly procedure. The two-port media 
reservoir was part of the overall bioreactor configuration, which will be diagramed in a 
later section. 
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Figure 3.15- Inlet and outlet tubing assembly of two-port media reservoir. A male luer 
lock barbed fitting is attached to the outlet and a female luer thread barbed fitting is 
attached to the inlet. 
 
 
Figure 3.16- Final completed assembly of two-port media reservoir. 
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Scaffold Setup and Insertion 
 The scaffold for the new Ideal BVM system was setup as follows. Expanded 
polytetrafluoroethylene (ePTFE), 3 mm and 4 mm inner diameter (Impra Bard, Inc., 
Tempe, AZ), was used as the scaffold material. Two white nylon, female luer thread style 
to 200 series barb fittings were inserted into the open ends of the ePTFE scaffold. White 
nylon, female luer thread style to 200 series barb, 1/8" ID tubing (Value Plastics P/N 
FTLL230-1) were used for the 4 mm inner diameter scaffolds and white nylon, female 
luer thread style to 200 series barb, 3/32" ID tubing (Value Plastics P/N FTLL220-1) 
were used for the 3 mm inner diameter scaffolds. The ends of the scaffold were sutured 
onto the barbed ends of the female luer thread fittings using 2.0 Sofsilk™ suture material. 
Figures 3.17 and 3.18 below illustrate this procedure. Depending on the number of male 
luer integral lock ring to female luer thread style couplers used between male-to-male 
rotating fittings, scaffolds were cut into either 5.5 cm, 4.5 cm or 3.5 cm lengths, 
corresponding to 0, 1, or 2 couplers respectively. See Table 3.1 below or Appendix E for 
a summary of scaffold length versus number of couplers used. 
 
Figure 3.17- Scaffold assembly. Two female luer thread barbed fittings were inserted into 
the open ends of the ePTFE scaffold. 
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Suture 
 
Figure 3.18- Completed scaffold assembly. The ends of the ePTFE scaffold were sutured 
to the two female luer thread barbed fittings. 
 
Illustration # of Couplers Scaffold Length 
 
0 5.5 cm 
 
1 4.5 cm 
 
2 3.5 cm 
Table 3.1- Scaffold length versus number of couplers used. 
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To secure the scaffold inside the Ideal BVM system, the female luer thread 
fittings attached to the scaffold were inserted into the male-to-male luer lock fittings 
attached to the luminal inlet and luminal outlet. The rotating collars of the male-to-male 
luer lock fittings were tightened around the female luer thread fittings attached to the 
scaffold. The inserted scaffold is illustrated below in Figure 3.19. 
 
Figure 3.19- Scaffold insertion. The scaffold is secured inside the BVM system by 
tightening the rotating collars of the male-to-male luer lock fittings around the female 
luer thread fittings attached to the scaffold. 
 
Bioreactor Configuration 
The complete bioreactor configuration consisted of the Ideal BVM system and 
two-port media reservoir connected in series. To construct the bioreactor system the male 
luer lock fitting attached to the two-port media reservoir outlet tubing was secured to the 
female luer thread fitting of the three-way stopcock attached to the luminal inlet of the 
Ideal BVM system. Next, the female luer thread fitting attached to the two-port media 
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reservoir inlet tubing was secured to the male luer lock fitting of the one-way stopcock 
attached to the main luminal outlet of the Ideal BVM system. This completed the Ideal 
BVM system bioreactor assembly. The Ideal BVM bioreactor system is illustrated in 
Figure 3.20 below. 
 
Figure 3.20- Ideal BVM system bioreactor configuration. 
 
Cost Analysis 
Due to the goal of creating a cost-effective, high-throughput testing environment, 
the cost of each individual component and part used to create the Ideal BVM system and 
two-port media reservoir was determined. The cost of all components and parts were 
summed and the total cost per individual completed Ideal BVM system and two-port 
media reservoir was calculated. 
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Functional Verification 
To verify that the Ideal BVM system and two-port media reservoir functioned 
properly without leakage, a complete bioreactor configuration was setup and used. A lab 
member completed a full sterile Ideal BVM setup including scaffold assembly and 
insertion, media injection, and connection of the Ideal BVM and two-port media reservoir 
in series. Flow through the bioreactor system was initiated by placing a section of the 
two-port media outlet tubing through a peristaltic pump. The Ideal BVM functional 
verification setup is illustrated in Figure 3.21 below. 
 
Figure 3.21- Ideal BVM functional verification setup. Flow was initiated by placing a 
section of the two-port media outlet tubing through a peristaltic pump. 
 
Peristaltic 
Pump 
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Comparison of Ideal BVM System to Original BVM System 
To compare the Ideal BVM system and the original BVM system a lab member 
completed a full sterile side-by-side setup of both systems. Setup included scaffold 
assembly and insertion, media injection, and connection of the BVM systems and two-
port media reservoirs in series. Flow through the bioreactor systems was initiated by 
placing a section of the two-port media outlet tubing through a peristaltic pump. The 
Ideal BVM system and original BVM system were compared and user feedback was 
gathered on overall usability, ease of scaffold insertion, user interface features, 
connections and fittings, bioreactor assembly, seal-ability, aseptic use and setup, and 
general component configuration. The user feedback survey can be found in Appendix F. 
 
Blood Vessel Development 
The Ideal BVM system was tested for its ability to cultivate an in vitro blood 
vessel mimic. Following scaffold insertion and priming of the system with media, human 
umbilical artery smooth muscle cells (HUASMC) were pressure sodded onto the luminal 
surface of the ePTFE scaffold.  The BVM system was placed in an incubator at 37 °C, 
5% CO2, and connected to a peristaltic pump. The pump generated flow through the 
lumen of the vessel over a time period of one day. After one day, the vessel was removed 
from the chamber and fixed in Histochoice for evaluation. Cell deposition and cell 
adherence to the vessel were evaluated using a scanning electron microscope. The fixed 
vessel was cut in half longitudinally and images of the luminal surface were acquired to 
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determine if the Ideal BVM system was capable of successfully supporting cell sodding 
and cultivation.  
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Results 
Ideal BVM System 
The Ideal BVM System was easy to assemble and build. All components were off 
the shelf and readily available, resulting in a design that was repeatable and consistent. 
No special tooling was needed and assembly was simple and straightforward. The leak-
proof snap and seal container was easy to work with and durable. Holes were drilled 
cleanly with a handheld power drill and an ordinary 15/64" drill bit. By threading the 
female luer lug panel mounts directly into the plastic the need for a large amount of 
adhesive was eliminated. The double o-ring design created a leak-proof seal and allowed 
for a clean and simple overall design. Tubing was easily attached to the barbed fittings 
exiting the chamber and female luer threads allowed for easy attachment of male-to-male 
rotating luer lock fittings. Male luer lock and female luer thread connectors and barbed 
fittings made tubing and stopcock assembly easy. Due to the simplicity of design, 
availability of components and easy assembly, it was possible to construct a large number 
of identical systems. Therefore, thirty Ideal BVM systems were constructed for 
immediate use. Assembled Ideal BVM systems are shown below in Figures 3.22 and 
3.23. 
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Figure 3.22- Ideal BVM System. 
 
 
 
 
Figure 3.23- Assembled Ideal BVM systems. Tubing was attached to the barbed fittings 
exiting the sides of the container (a) and male-to-male rotating fittings were attached to 
the female luer thread fittings extending into the chamber (b) and (c). The sealing double 
o-ring design (d) eliminated the need for a large amount of adhesive (e).   
(a) (b) 
(c) (d) (e) 
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Two-Port Media Reservoir 
Two-port media reservoir lids were also easy to assemble and build. The sealing 
double o-ring design eliminated the need for a large amount of adhesive and allowed for 
a clean and simple overall design, while providing a functional seal. Tubing was easily 
attached to the barbed fittings exiting the top of the lid and the 50 ml tube was easy to 
screw onto the lid. The female luer thread fittings exiting the bottom of the lid also made 
it easy to attach a short piece of tubing to create the outlet. Due to the simplicity of 
design, availability of components and easy assembly, thirty two-port media reservoirs 
were constructed for immediate use. Assembled two-port media reservoirs are shown 
below in Figures 3.24 and 3.25. 
 
Figure 3.24- Two-port media reservoir. 
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Figure 3.25- Assembled two-port media reservoirs. The sealing double o-ring design (a) 
eliminated the need for a large amount of adhesive (b). Tubing was attached to the barbed 
fittings exiting the top of the lid (c) and a short piece of tubing was secured to the female 
luer thread fitting exiting the bottom (d). Thirty two-port media reservoirs were 
constructed for immediate use (e). 
 
Scaffold Setup and Insertion 
Scaffold setup was simple and straightforward. The female luer thread barbed 
fittings were easy to insert into the ePTFE scaffold and the Sofsilk™ suture material was 
easy to tie and successfully secured the scaffold in place. The female luer thread barbed 
fittings were also easy to insert into the male-to-male rotating fittings within the Ideal 
(a) (b) 
(c) 
(d) (e) 
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BVM chamber. The rotating collars of the male-to-male luer lock fittings allowed 
insertion to be performed without bending or twisting of the scaffold material. The 
female luer thread end attached to the scaffold could be held in place while the male luer 
lock rotating collar was tightened around it. These features also permitted fast and 
asceptic insertion of the scaffold within the Ideal BVM chamber. Scaffold setup and 
insertion are shown below in Figures 3.26 and 3.27. 
 
Figure 3.26- Scaffold assembly. 
 
 
Figure 3.27- Scaffold insertion into Ideal BVM system. 
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An advantage of this new scaffold setup was that scaffold length and diameter 
were easily adjustable and variations were easily accommodated within the system. By 
choosing the correct size of female luer thread barbed fittings a number of diameters of 
ePTFE scaffold could be used. In addition, by using Table 3.1, scaffold length was easily 
adjustable by varying the number of couplers used in the inner BVM chamber assembly. 
The ability to vary scaffold length and diameter allows for the accommodation a large 
number of stents sizes to be tested within the Ideal BVM system. 
 
Bioreactor Configuration 
The complete bioreactor configuration, consisting of the Ideal BVM system and 
two-port media reservoir connected in series, was easy to setup with the need for only 
two simple connections. Specific placement of male luer lock and female luer thread 
fittings ensured proper setup and orientation every time. Only one configuration existed 
for setting up the bioreactor system, since the fittings of the Ideal BVM system and two-
port media reservoir were designed as male-to-female connections. This new design 
eliminated the confusion and complications faced in determining the correct inlet and 
outlet orientation when connecting the two-port media reservoir to the Ideal BVM 
system. The complete Ideal BVM bioreactor configuration is shown below in Figure 
3.28. 
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Figure 3.28- Complete bioreactor configuration. The Ideal BVM system and two-port 
media reservoir were connected in series. Specific placement of male luer lock and 
female luer thread fittings ensured proper setup and orientation every time. 
 
Cost Analysis 
The cost of each individual component and part used to create the Ideal BVM 
system and two-port media reservoir and the total cost per individual completed Ideal 
BVM system and two-port media reservoir is summarized in Tables 3.2 and 3.3 below. 
The total cost per individual completed Ideal BVM system was $9.71 and the total cost 
per individual completed two-port media reservoir was $5.54. The total cost of the 
completed bioreactor configuration, including both the Ideal BVM system and two-port 
media reservoir was $15.25. 
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Component Company Part Number 
Qty per 
BVM 
Cost per 
Unit 
Total 
Leak-Proof Chamber Lock & Lock HPL806 1 EA 3.00 3.00 
 Buna-N O-Ring McMaster-Carr 2418T112 6 EA 0.07 0.42 
Loctite 4011 Adhesive McMaster-Carr 1818A4 3 drops 0.02 0.06 
Female Luer Lug Panel 
Mount-1/8" Barb 
Value Plastics FTLB230-1 3 EA 0.17 0.51 
Lock Nut Value Plastics LNS-1 3 EA 0.08 0.24 
Male Luer Lock-1/8" 
Barb 
Value Plastics MTLL230-1 2 EA 0.14 0.28 
Female Luer Thread-
1/8" Barb 
Value Plastics FTLL230-1 2 EA 0.12 0.24 
Y-Connector-1/8" Barbs Value Plastics Y230-1 1 EA 0.22 0.22 
Male-Female Coupler Value Plastics LC34-1 2 EA 0.16 0.32 
1-Way Stopcock Value Plastics VP455980 2 EA 0.64 1.28 
3-Way Stopcock Value Plastics VPB1000079N 1 EA 0.64 0.64 
Male-to-Male Rotating 
Luer Lock 
Qosina 17664 2 EA 0.26 0.52 
1/8" ID Silicone Tubing Cole-Parmer WU-95702-06 11 inches 0.18 1.98 
     
$9.71 
 
Table 3.2- Total cost per individual completed Ideal BVM system. 
 
Component Company Part Number 
Qty per 
Reservoir 
Cost per 
Unit 
Total 
BD Falcon™ 50 ml 
Tube 
BD Biosciences 352098 1 EA 0.54 0.54 
Buna-N O-Ring McMaster-Carr 2418T112 4 EA 0.07 0.28 
Loctite 4011 Adhesive McMaster-Carr 1818A4 2 drops 0.02 0.04 
Female Luer Lug Panel 
Mount-1/8" Barb 
Value Plastics FTLB230-1 2 EA 0.17 0.34 
Lock Nut Value Plastics LNS-1 2 EA 0.08 0.16 
Male Luer Lock-1/8" 
Barb 
Value Plastics MTLL230-1 2 EA 0.14 0.28 
Female Luer Thread-
1/8" Barb 
Value Plastics FTLL230-1 1 EA 0.12 0.12 
1/8" ID Silicone Tubing Cole-Parmer WU-95702-06 21 inches 0.18 3.78 
     
$5.54 
 
Table 3.3- Total cost per individual completed two-port media reservoir. 
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Functional Verification 
The Ideal BVM system was used in conjunction with a two-port media reservoir 
and functioned properly without any leakage. The scaffold was inserted aseptically and 
the lid was easy to attach and created a leak-proof seal. The system was injected with 
media which was pumped through the system via a peristaltic pump. Flow was created 
through the luminal inlet and exited the luminal outlet and extra luminal outlet. The Ideal 
BVM systems were EO sterilized prior to use. Photos of the Ideal BVM system being 
setup and being attached to the peristaltic pump are shown below in Figures 3.29 and 
3.30. 
 
Figure 3.29- Setup of the Ideal BVM bioreactor system. The scaffold was inserted in an 
aseptic manner (a) and the two-port media reservoir and Ideal BVM were connected in 
series (b). 
 
(a) (b) 
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Figure 3.30- Attachment of the Ideal BVM bioreactor system to a peristaltic pump. The 
bioreactor system functioned properly without leakage.  
 
The luminal inlet, luminal outlet and extra luminal outlet configuration permitted 
variation in flow path. Transluminal and transmural flow were easily controlled via the 
one-way stopcock attached to the luminal outlet. By closing off the luminal outlet path, 
through the use of the one-way stopcock, transmural flow through the porous ePTFE 
scaffold wall was created, with flow exiting the extra luminal outlet. Transmural flow 
was used for conditioning and cell sodding of the scaffold material. By opening the one-
way stopcock, transluminal flow was restored through the luminal outlet. The one-way 
stopcock was easy to use and provided a quick and simple method for controlling the 
flow path. The lever was easy to turn and once in position flow was immediately and 
firmly blocked. The merging of the luminal outlet and extra luminal outlet into one main 
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outlet via the Y-connector made attachment to the two-port media reservoir simple with 
the need for only one connection. The three-way stopcock attached to the luminal inlet 
easily functioned as both a flow path and cell sodding port. With two female luer thread 
fittings, the three-way stopcock allowed the Ideal BVM system to be connected to the 
two-port media reservoir as well as maintain an extra port for cell sodding and media 
injection. 
Two-port media reservoirs were used in conjunction with the Ideal BVM system 
and also functioned properly without any leakage. Liquid was pulled from the media 
reservoir through the short outlet tube extending into the media and pumped through the 
bioreactor system via a peristaltic pump. Liquid drops could be seen falling from the inlet 
port, allowing for quick and easy visualization of flow as well as removal of air bubbles. 
Media reservoirs were EO sterilized prior to use. A photo of the media reservoir setup is 
shown below in Figure 3.31. 
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Figure 3.31- Two-port media reservoirs in use. The two-port media reservoirs functioned 
properly without leakage. Flow was established via a peristaltic pump. 
 
Comparison of Ideal BVM System to Original BVM System 
The Ideal BVM system and original BVM system were setup side-by-side by a 
lab member and a user feedback survey was completed which compared the two systems. 
Figures 3.32 and 3.33 below show the two systems being setup side-by-side and in the 
incubator connected to a peristaltic pump. The criteria evaluated and the results of the 
user feedback survey are summarized in Table 3.4. The completed user feedback survey 
can be found in Appendix F.  
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Figure 3.32- Side-by-side setup of original BVM and Ideal BVM systems. A lab member 
performed a sterile setup of both systems. 
 
 
Figure 3.33- Side-by-side setup of original BVM and Ideal BVM bioreactor systems. 
Both systems were setup in the incubator and connected to a peristaltic pump to create 
flow. 
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Original BVM System Ideal BVM System 
 
Difficult                Easy Difficult                 Easy 
Overall Usability 1       2     3     4     5 1       2     3     4     5 
Setup 1       2     3     4     5 1       2     3     4     5 
Scaffold Assembly 1       2     3     4     5 1       2     3     4     5 
Scaffold Insertion 1       2     3     4     5 1       2     3     4     5 
Media Injection 1       2     3     4     5 1       2     3     4     5 
Seal-Ability 1       2     3     4     5 1       2     3     4     5 
Aseptic Use 1       2     3     4     5 1       2     3     4     5 
Bioreactor Assembly 1       2     3     4     5 1       2     3     4     5 
Control of Flow 1       2     3     4     5 1       2     3     4     5 
Adjustability 1       2     3     4     5 1       2     3     4     5 
 
Awkward      Convenient Awkward      Convenient 
Components and Fittings 1       2     3     4     5 1       2     3     4     5 
 
Poor                Excellent Poor                Excellent 
Component Configuration 1       2     3     4     5 1       2     3     4     5 
Table 3.4- Summary of user feedback survey. The Ideal BVM system and original BVM 
system were compared based on the criteria listed. 
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Based on the user feedback survey comments one of the advantages of the Ideal 
BVM system was that the chamber lid can be sterilized separately from the rest of the 
BVM chamber. In addition, the lid is not permanently attached to BVM chamber, and 
does not need to be held open, freeing up a second hand for use during scaffold insertion 
and work in the hood. Both these features were helpful in maintaining sterility and made 
setup easier. Another noted advantage was that the four snapping latches of the lid 
eliminated the need for tools when closing and sealing the BVM chamber. The Ideal 
BVM system also utilized stopcocks instead of side clamps to control flow and since the 
BVM chamber is not filled to the top with media the need to eliminate air bubbles during 
setup was no longer a challenge. Finally, with inlet and outlet fittings arranged so that 
only one configuration exists to setup the bioreactor system time was not wasted and 
there was no confusion when connecting the Ideal BVM system to the two-port media 
reservoir.  
Based on the user feedback survey comments one of the disadvantages of the 
Ideal BVM system was that a larger volume of media was needed to fill the BVM 
chamber. Also, the larger container takes up more space in the incubator. However, it is 
important to note that the increased chamber volume only requires a one-time fill, as 
opposed to the reservoirs which are replaced every 3 days, and that these larger 
containers are stackable. The disadvantages, therefore, are offset by the advantages of the 
Ideal BVM system in comparison to the original BVM system. 
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Blood Vessel Development 
The Ideal BVM system successfully cultivated an in vitro blood vessel mimic by 
supporting cell sodding and cultivation. The scaffold was aseptically inserted and human 
umbilical artery smooth muscle cells (HUASMC) were pressure sodded onto the luminal 
surface of the ePTFE scaffold. Cells adhered to the scaffold surface and were distributed 
along the length of the vessel. Scanning electron microscope (SEM) images of an ePTFE 
scaffold surface are shown below in Figures 3.34 and 3.35. An SEM image of bare 
ePTFE, which represents the scaffold prior to cell sodding, is shown for reference 
followed by SEM images of the ePTFE with cells adhered to the surface. 
 
Figure 3.34- SEM image of bare ePTFE scaffold surface. 
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Figure 3.35- SEM images of ePTFE scaffold surface with cells. The Ideal BVM system 
successfully cultivated an in vitro blood vessel mimic with cell deposition and cell 
adherence to the scaffold surface. 
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Discussion and Conclusions 
The new Ideal BVM system and two-port media reservoirs were successfully built 
and implemented. The work described in this chapter supports the use of the Ideal BVM 
system for cultivation of in vitro blood vessel mimics. The finalized design and setup 
procedures were described in detail with testing performed to validate and verify the 
Ideal BVM bioreactor system functionality and use. The Ideal BVM incorporated a user 
friendly design and assembly was simple and straightforward. The scaffold was easy to 
insert without the need for bending or twisting. The leak-proof chamber was easy to seal 
and permitted quick and sterile assembly in the hood. Scaffold length and diameter were 
adjustable for greater testing variability. The chamber was optically clear allowing for 
easy visibility of scaffold, media and stent placement and was sterilizable by ethylene 
oxide (EO) gas. The Ideal BVM chamber was easy to manufacture without the need for 
adhesive or special tooling and was constructed of materials and components that were 
readily available and easy to obtain resulting in a low cost design that was easy to scale 
up. Multiple chambers could be configured in the incubator and the use of biocompatible 
materials allowed cells to grow and function.  
These findings support the hypothesis that design changes could be made and new 
configurations implemented to the original BVM system that would improve function 
and usability for preclinical device testing. Specifically, the work described in this 
chapter supports the hypothesis that a BVM chamber could be created which has the 
advantages of easy graft insertion and seal-ability, as well as the ability to accommodate 
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varying sizes of vessel scaffolds, all while maintaining the needs of a tissue engineering 
bioreactor system. 
Several other bioreactor systems currently exist for development of tissue 
engineered blood vessels (TEBV). Most of these systems, similar to the Ideal BVM 
system, use a peristaltic pump to create flow within an optically clear chamber. However, 
chamber design, scaffold orientation, and general configuration vary considerably. For 
example, a custom designed vertical bioreactor chamber was built which housed a non-
compliant silicone scaffold sodded with endothelial cells (EC) to examine the effects of 
shear stress and intravascular pressure (Punchard, et al. 2007). A second design utilized a 
large laboratory flask with sodding and cultivation of vascular smooth muscle cells 
(VSMC) on a PLCL [poly-(lactide-co-caprolactone)] scaffold oriented vertically within 
the chamber (Jeong, et al. 2005). These vertical bioreactor designs are shown below in 
Figure 3.36. Two other designs which examined the effects of pulsatile flow on smooth 
muscle and endothelial cell development utilized bioreactor systems that were very 
similar to the Ideal BVM system, with horizontal scaffold orientation (Hoerstrup, et al. 
2001; Engbers-Buijtenhuijs, et al. 2006). These systems were assembled so that many 
scaffolds could be cultivated at once. Figure 3.37 shows the basic schematics of these two 
horizontal systems. In comparison with these bioreactor systems, the Ideal BVM differed 
in that it was designed for the purpose of preclinical testing. Therefore, separate 
individual flow paths were needed for each system and the ability to scale-up was a large 
focus. However, in general, each bioreactor system for the development of tissue 
engineered blood vessels must be designed so that sterility is maintained at all times and 
flow can be created through a scaffold lumen. Designs differ based on the available 
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resources, desired features, purpose of the study, and designer ingenuity. In the case of 
the Ideal BVM system specific criteria were set in advance which guided the overall 
design.  
 
Figure 3.36- Vertical bioreactor chambers. 
 
 (Permission granted to reprint image from Punchard, et al. 2007 published in Journal of 
Biomechanics by Elsevier Limited.; Permission granted to reprint image from Jeong, et 
al. 2005 published in Biomaterials by Elsevier Limited.; see Appendix G) 
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Figure 3.37- Horizontal bioreactor systems. 
 
(Permission granted to reprint image from Hoerstrup, et al. 2001 published in European 
Journal of Cardio-Thoracic Surgery by Elsevier Limited.; Permission granted to reprint 
image from Engbers-Buijtenhuijs, et al. 2006 published in Biomaterials by Elsevier 
Limited.; see Appendix G) 
 
An additional advantage of the Ideal BVM system is that the basic design used to 
create the inlet and outlets of both the Ideal BVM chamber and two-port media reservoir 
can be easily applied to a wide range of container shapes and sizes. Depending on need 
and desired scaffold configuration holes can be placed in any location within the 
container. For example, a larger container could allow for longer scaffold lengths, or 
placement of inlet and outlet ports in varying configurations could accommodate more 
physiologic scaffold orientations, such as bends and bifurcations. Also, if additional ports 
are desired for injection of media into the space surrounding the scaffold, they can be 
easily added at any location desired.  It is important to note that as container length and 
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size increase so does container volume. Volume of the BVM chamber is not a critical 
factor, but does affect the amount of media needed to fill the system and should be 
considered prior to implementing a different container size.  
Given the possible variability of the general Ideal BVM chamber design, the 
following chapter will explore the potential to create alternate chambers for the 
evaluation of more complex vascular devices as well as the creation of chambers that 
accommodate more physiological vascular models. This idea of next generation BVM 
systems will be explored as potential future uses of the in vitro blood vessel mimic for 
preclinical device testing.  
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4. DESIGN OF NEXT GENERATION BVMs 
Introduction 
A BVM system can allow initial assessments to be performed on a large number 
of coating combinations and stent configurations in order to direct animal and clinical 
studies toward the most promising devices. The aim of the work in the previous chapters 
was to improve upon the original BVM system by developing a new, more ideal design 
and to describe in detail the finalized design, construction and setup of the Ideal BVM 
system and the testing performed to validate and verify its functionality and use.  
The design of both the original BVM and Ideal BVM systems focused on straight, 
simple scaffold orientations representing simple lesions and single vessel disease 
(Fournier, et al. 2005). Coronary stent implantation, however, is being performed in an 
increasing number of patients with a wide spectrum of clinical and lesion characteristics. 
The anatomical characteristics of coronary arteries vary considerably, ranging from 
straight simple geometries to extremely angulated bends and curves as well as 
bifurcations and long lesions (Ellis, et al. 1990; Zhu, et al. 2008; Smith, et al. 2001). 
Depending on the individual, the anatomical structure of the coronary arteries can include 
all or some of the characteristics identified above. These lesion characteristics, including 
long lesions, angulated geometries, and bifurcations, will be described in detail below 
and will provide an introduction to the aims of this chapter. 
The Ideal BVM system was designed to test stents ranging from 2.0-5.0 mm 
diameters and 8-38 mm lengths (Kandzari, Tcheng and Zidar 2002; Kraitzer, Kloog and 
Zilberman 2008), in order to accommodate the variations of coronary arteries observed in 
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clinical practice and the stents currently available in the market. However, single 
coronary lesions are often longer than 38 mm, sometimes greater than 60 mm in length, 
and treatment requires multiple overlapping stents (Ruchin, et al. 2008). Using the BVM 
system for preclinical testing of overlapping stents could allow for better understanding 
of the cellular response at the overlapping junctions as well as the effect of the potentially 
double local drug does when using drug-eluting stents (Kang, et al. 2007). In addition, 
new interlocking stent designs, such as the Custom NX(R) DES System manufactured by 
XTENT, Inc., are exploring the possibility of deploying stents up to 60 mm in total length 
(Stella, et al. 2008). Therefore, a BVM chamber for the preclinical testing of overlapping 
and longer total stent lengths would be beneficial.  
According to the American College of Cardiology/American Heart Association 
(ACC/AHA) Guidelines for Percutaneous Coronary Intervention, non-angulated coronary 
artery geometries are defined as bends that are less than 45°, while moderately angulated 
geometries represents bends between 45° and 90°, and extremely angulated geometries 
are considered bends in excess of 90° (Smith, et al. 2001). A variety of angled geometries 
are illustrated below in Figure 4.1. Figure 4.2 is an X-ray angiogram image of the 
coronary arteries and shows the variation of curvatures observed in clinical practice. 
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Figure 4.1- Coronary artery geometries. Non-angulated bends are between 0° (a) and 45° 
(b), moderately angulated bends are between 45° and 90° (c), and extremely angulated 
geometries are greater than 90°. Examples of extremely angulated geometries are shown 
as 135° (d) and 180° (e). 
 
 
 
 
 
c) b) a) 
e) d) 
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Figure 4.2- X-ray angiogram image of the coronary arteries. Various angled bends and 
curvatures are present. 
 
(Permission granted to reprint image from Xu, et al. 2007 published in Computer 
Methods and Programs in Biomedicine by Elsevier Limited.; see Appendix G) 
 
As mentioned previously, the Ideal BVM system was designed for straight, 
simple scaffold orientations representing simple lesions and ideal anatomical geometry. 
In clinical practice, however, coronary arteries are not straight and uniform. They run 
along the surface of the heart and are curved, bent, and angulated (Smith, et al. 2001). In 
addition, it has been observed that plaque accumulation is related to vessel curvature, 
with plaque accumulating more rapidly in angulated vessels where wall shear stress is 
low (Wahle, et al. 2006; Zhu, et al. 2008). As a result, stents are most often placed in 
curved positions within the coronary arteries and remain in a bent position throughout 
their lifetime (Fournier, et al. 2005; Smith, et al. 2001). Many coronary stents, such as the 
MULTI-LINK manufactured by Abbott Vascular, CYPHER
®
 manufactured by Cordis, 
  
 
131 
 
and TAXUS
®
 manufactured by Boston Scientific, also claim superior flexibility and 
conformity which allow the stent to mold to the natural contours of the vessel wall 
(Serruys and Gershlick 2005; Rieu, et al. 2003). Therefore, a BVM chamber for the 
preclinical testing of devices in curved and angulated vessels would be beneficial and 
would represent a more physiological blood vessel mimic model. 
As described by the ACC/AHA a coronary bifurcation occurs when one main 
vessel branches out into two smaller vessels, one being the continuation of the main 
vessel, and the other referred to as the side branch (Smith, et al. 2001). A coronary 
bifurcation lesion is defined as a narrowing involving both the main vessel and a 
significant side branch (Louvard, et al. 2008). Illustrations of two bifurcated geometries, 
Y-shaped and T-shaped, are shown below in Figure 4.3. Figure 4.4 is an X-ray angiogram 
image of Y-shaped and T-shaped bifurcations observed in clinical practice. 
 
Figure 4.3- Bifurcated coronary artery geometries. Y-shaped (a) and T-shaped (b). 
a) b) 
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Figure 4.4- X-ray angiogram image of bifurcated coronary arteries.  
Y-shaped (a) and T-shaped (b). 
 
(Permission granted to reprint image from Ikeno, Buchbinder and Yeung 2007 published 
in Cardiovascular Revascularization Medicine by Elsevier Limited.; see Appendix G) 
 
Bifurcation lesions account for 15-18% of all coronary lesions and represent one 
of the most complex coronary lesions to treat since the lumen of both the main vessel and 
side branch are affected and require treatment (Sukhija, Mehta and Sachdeva 2008). 
Recent advances have allowed physicians to treat bifurcation lesions, where both the 
main vessel and side branch need to be restored. Many techniques, with the use of one or 
multiple stents, have been developed to treat bifurcation lesions (Sukhija, Mehta and 
Sachdeva 2008; Iakovou, Ge and Colombo 2005). The simplest approach is to stent the 
main vessel and dilate the side branch through the stent struts. A second approach is to 
use multiple stents and can be accomplished through a number of different techniques 
which were discussed in Chapter 1: V-stenting, simultaneous kissing, crush, T-stenting, 
modified T-stenting, Y-stenting, and skirt. Most recently, novel stents and delivery 
a) b) 
  
 
133 
 
systems such as AXXESS™ manufactured by Devax, Inc., PETAL™ manufactured by 
Boston Scientific, and MULTI-LINK Frontier manufactured by Abbott Vascular have 
been developed specifically to treat bifurcation lesions (Grube, et al. 2007; Ikeno, 
Buchbinder and Yeung 2007; Miyazawa, et al. 2007; Lefèvre, et al. 2005). Therefore, a 
BVM chamber for the preclinical testing of devices in bifurcation shaped vessels would 
be beneficial and would support advancing technology. 
In summary, the variation and complexity of coronary artery disease and the 
advanced capabilities to detect and determine the extent and severity of coronary lesions 
has led to an increased interest in intravascular device innovation (Kini 2006). Stents are 
most often placed in vessels with angulated geometries and remain in bent positions 
throughout their lifetime (Fournier, et al. 2005; Smith, et al. 2001). Long lesions can 
require two overlapping stents (Ruchin, et al. 2008) and bifurcation lesions often require 
two stents at varying angles or the use of a novel stent specifically designed for a 
bifurcation (Sukhija, Mehta and Sachdeva 2008; Ikeno, Buchbinder and Yeung 2007). 
Thus, the aim of the work in this chapter was to expand the BVM concept to meet the 
need of future technologies that currently have not been adequately addressed in 
preclinical models, such as long, angulated and bifurcation lesions. The hypothesis was 
that the need to test stents specifically for long, angulated and bifurcation lesions can be 
potentially addressed by using modified BVM systems. Although full implementation 
and testing of these models is beyond the scope of this thesis, the current work will 
explore the development of new and innovative models for the evaluation of more 
complex lesions as well as the creation of chambers that accommodate more 
physiological vascular models and scaffold orientations. Therefore, this chapter will 
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explore the creation of alternate chambers for the evaluation of more complex vascular 
devices as potential future uses of the in vitro blood vessel mimic for preclinical device 
testing. 
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Next Generation BVM System Designs 
BVM System for Long Vessels 
A BVM system for long vessels can be created by using a longer chamber, such 
as the 800 ml, 8" x 5" x 2", semitransparent, polypropylene rectangular snap and seal 
leak-proof food container (Lock & Lock P/N HPL816) and implementing the same 
design and construction described in the previous chapter and detailed in Appendix C for 
the assembly of the luminal inlet and luminal outlets. Locations of the luminal inlet and 
luminal outlets are identical to the Ideal BVM system. A chamber of this size can 
accommodate scaffold lengths up to 170 mm which would allow long or multiple stents 
to be placed and overlapped within the vessel lumen. It is important to note that the 
volume of this chamber is greater than that of the Ideal BVM system. Volume of the 
BVM chamber is not a critical factor, but does affect the amount of media needed to 
initially fill the system and should be considered prior to implementation. The BVM 
system for long vessels is modeled below in Figures 4.5 and 4.6. 
 
Figure 4.5- BVM system for long vessels. 
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Figure 4.6- Scaffold setup for long vessels. Longer scaffold lengths can be 
accommodated in a modified BVM system by using a longer chamber.  
 
Scaffold setup and insertion for the BVM system for long vessels will remain 
unchanged from the assembly process used for the Ideal BVM system described in the 
previous chapter, except for the length of ePTFE scaffold used. As in the previous design, 
male luer integral lock ring to female luer thread style couplers can be used to vary the 
overall scaffold length. A prototype of this model would be needed to establish the 
corresponding scaffold length versus number of couplers used.  
The design of the BVM system for long vessels is almost identical to the Ideal 
BVM system and implements a chamber that is identical except for length and volume. 
As a result the BVM chamber for long vessels meets all of the design criteria established 
in the previous chapters.  
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BVM System for Angulated Vessels 
A BVM system for angulated and curved vessels can be created by varying the 
placement of the luminal inlet and luminal outlet holes on the Ideal BVM chamber. 
Construction of the luminal inlet and luminal outlet holes can be accomplished using the 
same materials and methods described in the previous chapter and detailed in Appendix 
C. Prototypes must be built in order to determine the exact dimensional location and 
placement of the luminal inlet and luminal outlet holes. However, the illustrations below 
approximate their general locations. A large variation of curves and angles can be created 
ranging from slight bends to 180° turns, representing non-angulated, moderately 
angulated and severely angulated geometries. Construction of several modified BVM 
chambers for angulated vessels are described below. All designs utilize the same chamber 
as the Ideal BVM system, a 350 ml, 4" x 5" x 2", semitransparent, polypropylene 
rectangular snap and seal leak-proof food container (Lock & Lock P/N HPL806). 
The simplest bend that can be created requires only one change to the tubing 
configuration of the Ideal BVM system. Locations of the luminal inlet and luminal outlet 
holes are identical to the Ideal BVM system. By reversing the placement of the luminal 
outlet and extra luminal outlet and connecting the scaffold as described in the previous 
chapter, a slightly bent scaffold can be accommodated. This setup represents a non-
angulated geometry and can accommodate scaffold orientations with bends of 45° or less. 
The BVM system for slightly bent vessels is modeled below in Figures 4.7 and 4.8. 
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Figure 4.7- BVM system for slightly bent vessels. 
 
 
Figure 4.8- Scaffold setup for non-angulated vessels. A slightly bent scaffold can be 
accommodated in a modified BVM chamber by reversing the luminal outlet and extra 
luminal outlet positions. 
 
The second bend that can be created requires only a slight modification to the 
configuration of the Ideal BVM system. By moving the luminal outlet and extra luminal 
outlet to the long side of the chamber and connecting the scaffold as described in the 
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previous chapter, a moderately angled scaffold can be accommodated. This setup 
represents moderately angled geometry and can accommodate a scaffold orientation with 
a bend of 90°. The BVM system for moderately angled vessels is modeled below in 
Figures 4.9 and 4.10. 
 
Figure 4.9- BVM system for moderately angled vessels. 
 
 
Figure 4.10- Scaffold setup for moderately angulated vessels. A moderately angled 
scaffold of 90° can be accommodated in a modified BVM chamber by moving the 
luminal outlet and extra luminal outlet to the long side of the chamber. 
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The third bend that can be created requires a minor modification to the 
configuration of the Ideal BVM system. By moving the luminal inlet, luminal outlet and 
extra luminal outlet to the long side of the chamber and connecting the scaffold as 
described in the previous chapter, a severely angled scaffold can be accommodated. This 
setup represents severely angled geometry and can accommodate a scaffold orientation 
with a bend of 180°. The BVM system for severely angled vessels is modeled below in 
Figures 4.11 and 4.12. 
 
Figure 4.11- BVM system for severely angled vessels. 
 
  
 
141 
 
 
Figure 4.12- Scaffold setup for severely angulated vessels. A severely angled scaffold of 
180° can be accommodated in a modified BVM chamber by moving the luminal inlet, 
luminal outlet and extra luminal outlet to the long side of the chamber. 
 
Scaffold setup and insertion for the BVM systems for angulated vessels will 
remain unchanged from the assembly process used for the Ideal BVM system described 
in the previous chapter, except for the lengths of ePTFE scaffolds used. As in the 
previous design, male luer integral lock ring to female luer thread style couplers can be 
used to vary the overall scaffold lengths in each design. Prototypes of each model are 
needed to establish the corresponding scaffold lengths versus number of couplers.  
One challenge that may be encountered in these configurations is kinking and 
occlusion of the scaffolds due to their bent orientations. However, ePTFE material is 
flexible and compliant and once flow is created via a peristaltic pump, the force on the 
scaffold walls created by the pressure of the media may be strong enough to overcome 
any kinks or occluded bends that occur. This hypothesis will need to be verified and 
tested with full-scale prototypes. If kinking or occlusion proves to be a challenge a 
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change in the scaffold material or fabrication method may need to be addressed. Pre-
forming the scaffold in a bent orientation by using a mold or customized model could 
provide a solution. A thin wire coiled around the outside of the ePTFE could also be used 
to control the curvature and orientation without disrupting the inner lumen. 
The designs of the BVM systems for angulated vessels are almost identical to the 
Ideal BVM system and use the exact same chamber. As a result the BVM chambers for 
angulated vessels meet all of the design criteria established in the previous chapters.  
 
BVM System for Bifurcation Vessels 
A BVM system for bifurcation vessels can be created by varying the placement of 
the luminal inlet, luminal outlet, and extra luminal outlet holes and adding a second 
luminal outlet to accommodate the side branch lumen. Construction of the luminal inlet 
and luminal outlet holes can be accomplished using the same materials and methods 
described in the previous chapter and detailed in Appendix C. Prototypes must be built in 
order to determine the exact dimensional location and placement of the luminal inlet and 
luminal outlet holes. However, the illustrations below approximate their general 
locations. The most notable change is the modified tubing configuration which is 
necessary to accommodate flow through the second luminal outlet. Construction of two 
modified BVM chambers for Y-shaped and T-shaped bifurcation vessels are described 
below. Each design utilizes the same chamber as the Ideal BVM system, a 350 ml, 4" x 
5" x 2", semitransparent, polypropylene rectangular snap and seal leak-proof food 
container (Lock & Lock P/N HPL806). 
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The first bifurcation geometry that can be created requires some modifications to 
the configuration of the Ideal BVM system. By moving the extra luminal outlet to the 
long side of the chamber and adding a second luminal outlet in its place a Y-shaped 
bifurcation scaffold can be accommodated. A Y-shaped bifurcation scaffold can be setup 
and connected as described in the previous chapter with the addition of one female luer 
thread style to 200 series barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1). One 
male-to-male luer lock connector, with one rotating collar (Qosina P/N 17644) also needs 
to be attached to the second outlet to hold the scaffold. The easiest way to configure the 
tubing is to simply add a second Y-connector with 200 series barbs, 1/8" ID tubing 
(Value Plastics P/N Y230-1) prior to the attachment of the one-way stopcock. In addition, 
a second one-way stopcock (Value Plastics P/N VP455980) must be added to the second 
luminal outlet to control flow. This modified orientation represents Y-shaped bifurcation 
geometry and can accommodate a Y-shaped scaffold. The BVM system for Y-shaped 
bifurcation vessels is modeled below in Figures 4.13 and 4.14. 
 
Figure 4.13- BVM system for Y-shaped bifurcation vessels. 
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Figure 4.14- Scaffold setup for Y-shaped bifurcation vessels. A Y-shaped bifurcation 
scaffold can be accommodated in a modified BVM chamber by moving the extra luminal 
outlet to the long side of the chamber and adding a second luminal outlet in its place. 
 
The second bifurcation geometry that can be created requires one simple 
modification to the configuration of the Ideal BVM system. By adding a second luminal 
outlet to the long side of the chamber a T-shaped bifurcation scaffold can be 
accommodated. A T-shaped bifurcation scaffold can be setup and connected as described 
in the previous chapter with the addition of one female luer thread style to 200 series 
barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1). One male-to-male luer lock 
connector, with one rotating collar (Qosina P/N 17644) also needs to be attached to the 
second outlet to hold the scaffold. The easiest way to configure the tubing is to simply 
add a second Y-connector with 200 series barbs, 1/8" ID tubing (Value Plastics P/N 
Y230-1) prior to the attachment of the one-way stopcock. In addition, a second one-way 
stopcock (Value Plastics P/N VP455980) must be added to the second luminal outlet to 
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control flow. This modified orientation represents T-shaped bifurcation geometry and can 
accommodate a T-shaped scaffold. The BVM system for T-shaped bifurcation vessels is 
modeled below in Figures 4.15 and 4.16. 
 
Figure 4.15- BVM system for T-shaped bifurcation vessels. 
 
 
Figure 4.16- Scaffold setup for T-shaped bifurcation vessels. A T-shaped bifurcation 
scaffold can be accommodated in a modified BVM chamber by adding a second luminal 
outlet to the long side of the chamber. 
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Scaffold setup and insertion for the BVM systems for bifurcation vessels will 
remain unchanged from the assembly process used for the Ideal BVM system described 
in the previous chapter. However, Y-shaped and T-shaped bifurcation ePTFE scaffolds 
will need to be constructed. Sewing standard ePTFE material together in the desired 
shape could provide a feasible method and is illustrated in Figures 4.17 and 4.18 below.  
 
Figure 4.17- Y-shaped bifurcation scaffold. Constructed by sewing three short pieces of 
ePTFE material together. 
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Figure 4.18- T-shaped bifurcation scaffold. Constructed by creating a hole in the center 
of a long piece of ePTFE material and sewing a short piece of ePTFE material to the hole. 
 
One challenge that may be encountered with this assembly process is leakage at 
the suture sites. Prototype scaffolds will need to be constructed and inserted into the 
BVM chambers and flow via a peristaltic pump will need to be initiated to evaluate the 
potential leakage. Using a mold or customized model to form the entire scaffold in a 
bifurcation shape could also provide a solution and would eliminate the possibility of 
leakage, although a material other than ePTFE would need to be chosen and evaluated. 
As in the previous design, male luer integral lock ring to female luer thread style couplers 
can be used to vary the overall scaffold lengths in each design. Prototypes of each model 
are needed to establish the corresponding scaffold lengths versus number of couplers. 
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The designs of the BVM systems for bifurcation vessels are very similar to the 
Ideal BVM system and use the exact same chamber. As a result the BVM chambers for 
bifurcation vessels meet all of the design criteria established in the previous chapters.  
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Next Generation BVM System Prototypes 
Six modified BVM systems representing complex coronary vessel geometries 
were modeled above: long, slightly bent, moderately angulated, severely angulated, Y-
shaped bifurcation and T-shaped bifurcation. Although full implementation and testing of 
these models is beyond the scope of this thesis, a multipurpose and Y-shaped bifurcation 
BVM system prototype were built with the intention of verifying the feasibility of these 
designs. The only configuration that was not prototyped was the BVM system for long 
vessels, since the configuration is identical to the Ideal BVM system with the exception 
of a longer chamber. 
 
Multipurpose BVM System 
Instead of building each individual BVM system prototype, a multipurpose BVM 
system was built with appropriate luminal inlets and luminal outlets to accommodate 
complex vessel configurations. This modified BVM chamber accommodated slightly 
bent, moderately angulated, severely angulated, and T-shaped bifurcation configurations. 
The luminal inlets and luminal outlets that were not required for a specific configuration 
were simply occluded using a male luer integral lock ring plug (Value Plastics P/N LP4-
1). As proposed, two pieces of ePTFE material were sutured together to make the T-
shaped bifurcation scaffold. The multipurpose BVM system prototype, with a slightly 
bent scaffold, a moderately angulated 90° scaffold, a severely angulated 180° scaffold, 
and a T-shaped bifurcation scaffold are shown below in Figures 4.19 through 4.22. 
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Figure 4.19- Multipurpose BVM System with a slightly bent scaffold. 
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Figure 4.20- Multipurpose BVM System with a moderately angulated 90° scaffold. 
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Figure 4.21- Multipurpose BVM System with a severely angulated 180° scaffold. 
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Figure 4.22- Multipurpose BVM System with a T-shaped bifurcation scaffold. 
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Y-Shaped Bifurcation BVM System 
A Y-shaped bifurcation BVM system was built with appropriate luminal inlets 
and luminal outlets to accommodate a Y-shaped bifurcation vessel configuration. 
However, instead of suturing three separate piece of ePTFE together, as purposed, a 
simpler method was used. Due to the flexibility of ePTFE material and the desire to use 
as few sutures as possible, the arms of the T-shaped scaffold were bent upwards to create 
a Y-shaped scaffold. This method eliminated the need for three separate ePTFE pieces to 
be sutured together, reducing the chance of leakage at the suture points. The Y-Shaped 
Bifurcation BVM system prototype is shown below in Figure 4.23. 
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Figure 4.23- Y-Shaped Bifurcation BVM System with a Y-shaped bifurcation scaffold. 
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Discussion and Conclusions 
The next generation BVM systems, presented through computer-generated 
models and initial prototypes, represent the development of new and innovative designs 
for the evaluation of more complex lesions that currently have not been adequately 
addressed in preclinical models and support the hypothesis that the Ideal BVM system 
can be modified to accommodate advancing technology. The work in this chapter 
expanded the BVM concept to meet the needs of long, angulated and bifurcation lesions. 
Alternate chambers for the evaluation of more complex vascular devices, as potential 
future uses of the in vitro blood vessel mimic for preclinical device testing, were 
illustrated and prototyped. 
Full implementation and testing of the modified BVM systems was beyond the 
scope of this thesis. Additional prototypes and verification testing is needed to 
demonstrate that the modified BVM systems developed in this chapter meet the testing 
needs for long, angulated and bifurcation lesions. The prototypes of each modified BVM 
chamber need to be finalized and the entire bioreactor system needs to be assembled and 
connected to a peristaltic pump. Scaffolds for each system also need to be assembled, 
measured and connected to the modified BVM systems to establish lengths, and evaluate 
the possibility for kinking or occlusion due to bent orientations. Bifurcation scaffolds will 
need to be constructed and evaluated for their ability to function under pressure and flow 
conditions.  
The first step in the evaluation of each model requires full construction of the 
modified BVM systems. Construction of the modified BVM chambers utilize the same 
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materials and methods described in the previous chapter and detailed in Appendix C. 
Location of the luminal inlets and outlets vary between models, but the assembly process 
remains unchanged. The construction of a multipurpose and Y-shaped bifurcation BVM 
chamber prototype and the assembly of each complex vessel scaffold configuration 
within these chambers were shown, verifying the feasibility of these designs. 
The complete bioreactor configurations, although not illustrated in this chapter, 
consist of the modified BVM systems and two-port media reservoirs, described in the 
previous chapter, connected in series. Setup is identical to the Ideal BVM bioreactor 
configuration and only two simple connections need to be made. Specific placement of 
male luer lock and female luer thread fittings ensure proper setup and orientation every 
time. Only one configuration exists for setting up the modified BVM bioreactor systems, 
since the fittings of all modified BVM chambers and two-port media reservoirs were 
designed as male-to-female connections. 
The luminal inlet, luminal outlets and extra luminal outlet tubing configurations 
are identical to the Ideal BVM system and permit variation in flow path. Transluminal 
and transmural flow are easily controlled via the one-way stopcocks attached to the 
luminal outlets. For the bifurcation models, one-way stopcocks are attached to both the 
main vessel luminal outlet and the side branch luminal outlet, allowing control of flow 
through each of the bifurcation paths. By closing off the luminal outlet paths, through the 
use of the one-way stopcocks, transmural flow through the porous ePTFE scaffold walls 
is created, with flow exiting the extra luminal outlets. Transmural flow is used for 
conditioning and cell sodding of the scaffold material. By opening the one-way 
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stopcocks, transluminal flow is restored through the luminal outlets. The one-way 
stopcocks are easy to use and provide a quick and simple method for controlling the flow 
paths. The levers are easy to turn and once in position flow is immediately and firmly 
blocked. The merging of the luminal outlets and extra luminal outlets into one main 
outlet via Y-connectors make attachment to the two-port media reservoir simple with the 
need for only one connection. The three-way stopcocks attached to the luminal inlets 
easily function as both flow paths and cell sodding ports. With two female luer thread 
fittings, the three-way stopcocks allow the modified BVM systems to be connected to the 
two-port media reservoirs as well as maintain an extra port for cell sodding and media 
injection. 
Few models, other than animal and clinical studies, exist for preclinical testing of 
complex intravascular devices designed specifically for placement in complex coronary 
lesion geometries. Currently most preclinical biocompatibility and tissue response testing 
is done on animals in outside laboratories which is both time consuming and expensive, 
especially when testing involves device placement and orientation in long, angulated and 
bifurcation vessels. Although preclinical animal studies are accepted as a means to 
predict the probability of device safety and effectiveness in humans, the need exists for 
preclinical testing using live human tissue. Preclinical testing using human cells would 
greatly increase the medical community’s understanding of tissue response to complex 
intravascular devices prior to animal and patient testing and prior to device release into 
the market. Presently, it is difficult to simulate device and tissue interaction and research 
still needs to be done to fully understand tissue behavior and the in vivo interaction that 
occurs between device and tissue in complex coronary lesion geometries.  
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In order to address some of these limitations, there has been research on the use of 
alternate or in vitro models for this type of complex device testing.  One research group 
that wanted to evaluate the use of coronary stents in the side branch of a bifurcation 
lesion constructed a testing model made of Plexiglas with a 4.5 mm bifurcation shaped 
trough bored out of the center in order to simulate a bifurcation vessel (Ormiston, et al. 
1999). This type of synthetic model approach is not uncommon, and the model does 
allow stents to be deployed and evaluated in a bifurcated geometry, however no cellular 
lining exists to provide physiological response evaluations. A second research group that 
wanted to evaluate the response of endothelial cells to flow hemodynamics at an arterial 
bifurcation apex constructed a T-shaped bifurcation in vitro flow chamber (Szymanski, et 
al. 2008). This chamber was custom designed and constructed of polycarbonate, stainless 
steel, and nylon, which are all autoclavable materials. This model, unlike the previous 
model, was constructed for the purpose of establishing a cellular lining at the bifurcation 
apex. However, intravascular devices were not deployed in this model and it is not clear 
if the design allows for this type of evaluation. 
With increasing complexity of coated stents and devices that interface with cells 
and tissue (Waksman 2007; Waksman 2002; Sharkawi, et al. 2007) the ability to evaluate 
in a living environment is crucial. The modified BVM systems developed in this chapter 
were designed to support the growth of 3-dimensional in vitro tissue engineered blood 
vessel mimics in order to provide physiological models of complex coronary geometries. 
With advancing technology these modified BVM systems may one day provide an ideal 
environment for evaluation of complex vascular devices and direct animal and clinical 
studies toward the most promising advances. 
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5. DISCUSSION AND CONCLUSIONS 
To summarize, the work in this thesis describes the design and optimization of an 
in vitro blood vessel mimic (BVM) bioreactor system for the evaluation of intravascular 
devices, specifically coronary stents, in simple and complex vessel geometries. The 
general hypothesis driving this thesis project was that design changes could be made and 
new configurations implemented to the existing blood vessel mimic system (Cardinal, et 
al. 2006) that would improve function and usability for preclinical device testing. In order 
to test this hypothesis, research was conducted based on two specific aims. The first aim 
was to develop a more ideal BVM system. The specific hypothesis in this case was that a 
BVM chamber could be created to accommodate a wider range of stent lengths and 
diameters, while allowing for easy graft insertion and seal-ability. The second aim was to 
develop next generation BVM systems, focused on future needs and technology. The 
hypothesis in this case was that with emerging technology the ability to test stents 
specifically for bifurcation lesions, as well as in long and angulated vessels, will be 
needed and is possible within the BVM system. The prototypes developed and the 
findings from constructed models were presented and discussed in the previous chapters 
and support the hypotheses stated above.  
The more ideal BVM bioreactor system designed and developed in this thesis was 
successfully built and implemented. A more user friendly design was one of the primary 
needs met by the Ideal BVM system. Easy scaffold insertion, without the need for 
bending or twisting, along with a method to quickly and simply seal the vessel chamber 
without the need for tools, greatly improved the usability of the BVM system. As 
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discussed in detail in the introduction to this thesis, stents range in shape and size, and the 
Ideal BVM system was designed to accommodate stent sizes ranging from 2.0-5.0 mm 
diameters and 8-38 mm lengths in order to fit the variations of coronary arteries observed 
in clinical practice and the stents currently available in the market. In addition, the Ideal 
BVM chamber was easy to manufacture without the need for adhesive or special tooling 
and was constructed of materials and components that were readily available and easy to 
obtain resulting in a low cost design that was easy to scale up. Multiple chambers could 
be configured in the incubator and the use of biocompatible materials allowed cells to 
grow and function. Therefore, the work described in this thesis supports the use of the 
Ideal BVM system for cultivation of in vitro blood vessel mimics. 
The next generation BVM systems, presented in this thesis through computer-
generated models and initial prototypes, represent the development of new and innovative 
designs for the evaluation of more complex lesions that currently have not been 
adequately addressed in preclinical models. The work presented supports the hypothesis 
that the Ideal BVM system can be modified to accommodate advancing technology. 
Alternate chambers for the evaluation of more complex vascular devices, as potential 
future uses of the blood vessel mimic system for preclinical device testing, were 
illustrated and prototyped. Full implementation and testing of the modified BVM systems 
was beyond the scope of this thesis. However, the construction of a multipurpose and Y-
shaped bifurcation BVM chamber prototype and the assembly of each complex vessel 
scaffold configuration within these chambers were shown, verifying the feasibility of 
these designs. With advancing technology, these modified BVM systems may one day 
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provide an ideal environment for evaluation of complex vascular devices in order to 
direct animal and clinical studies toward the most promising technologies. 
The goal of this thesis was to not only expand upon the original BVM model, but 
to develop new and innovative models for the evaluation of devices in more complex 
geometries such as bifurcations, long and angulated vessels. The BVM systems 
developed in this thesis are model systems which were developed for the initial testing of 
newly emerging intravascular technology, and represent the next step in preclinical 
device testing. In the following sections, key aspects of this field and relevant areas of 
research will be discussed with regard to the present thesis work. 
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Preclinical Intravascular Device Testing 
Preclinical device testing is a crucial step in the process of developing and 
releasing new medical devices to the market. The objective of preclinical testing is to 
provide preliminary evidence of product safety and efficacy in order to support the 
initiation of human clinical trials. Preclinical testing typically begins using models and 
methods that are simple and cost-effective in order to identify potential failures as early 
in the development process as possible, and then progresses to models with increasing 
complexity. As discussed in the introduction, preclinical intravascular device testing is 
currently performed using both in vitro laboratory models and in vivo animal models and 
provides critical information about cellular and tissue responses as well as device 
success. 
Although preclinical animal studies are accepted as a means to predict the 
probability of device safety and effectiveness in humans, no animal model can provide 
complete insights into the human healing response following stent implantation. 
Preclinical testing using human cells would greatly increase the medical community’s 
understanding of tissue response to a specific device prior to animal and patient testing 
and prior to device release. The Ideal BVM system developed in this thesis represents an 
intermediate testing environment for assessing human cellular responses to intravascular 
stents in a manner that combines the advantages of both in vitro and in vivo approaches. 
The Ideal BVM system mimics the geometries of the coronary arteries and utilizes 
human cells, which provide the potential for more predictive preclinical results than 
animal models alone can provide. The Ideal BVM system developed in this thesis 
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provides a feasible method to rapidly evaluate human tissue response to varying stent 
configurations, materials, drugs and coatings as they become available. Although the 
Ideal BVM system is not a substitute or replacement for animal models, it has the 
potential to provide researchers with a more relevant in vitro tissue model that can be 
used for the preclinical evaluation of new intravascular devices. The major advantage of 
the in vitro blood vessel mimic system developed in this thesis is its potential for 
consistent high-throughput evaluation of cellular response to advancing intravascular 
technologies (Cheng, Lai and Kisaalita 2008; Yliperttula, et al. 2008). 
 
Laminar Flow and Wall Shear Stress 
One area that has not yet been addressed as a potential use for the blood vessel 
mimic (BVM) bioreactor systems developed in this thesis is the study of laminar flow 
and wall shear stress in stented vessels. Implanted stents can alter coronary flow and 
induce significant changes in flow hemodynamics, especially in bifurcated and angulated 
geometries where flow is already disturbed and shear stress is low (Zhu, et al. 2008; 
Wahle, et al. 2006; Benard, et al. 2003). These changes result in local modification of the 
mechanical stress exerted on the endothelial cells lining the vessel wall and several 
studies have demonstrated that endothelial cell proliferation increases significantly when 
subjected to weak shear stress and non-laminar flow (Ridger, et al. 2008; Scott 2006).  
A number of experiments have been performed to study the influence of an 
implanted stent on flow hemodynamics through a stented vessel (Peacock, et al. 1995; 
Benard, et al. 2003). However, most of these studies used computer generated 
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computational techniques rather than animal or in vitro physical models (Balossino, et al. 
2008; Dehlaghi, Shadpoor and Najarian 2008). As a result, the influence of flow 
disturbances on the healing response to an implanted stent is poorly understood and the 
need exists for anatomically realistic testing models with cellular linings to obtain more 
predictive preclinical results.  
The use of the BVM systems developed in this thesis to study flow 
hemodynamics in stented vessels could provide important information about the 
influence of flow and shear stress on vascular healing. The BVM system could be used to 
not only study the cellular response to laminar flow and shear stress changes due to the 
presence of a stent, but could provide a model that would simultaneously allow for direct 
flow and velocity measurements. The BVM bioreactor system created in this thesis is a 
closed system in which all physical parameters, including flow, can be tightly controlled 
and monitored while allowing visualization and access to the inner lumen of the stented 
vessel. These advantages make the in vitro BVM system an ideal model for the study of 
flow hemodynamics. 
 
Drug Elution Kinetics 
Blood flow through a stented vessel not only affects laminar flow and wall shear 
stress, but plays a direct role on drug elution kinetics, or drug release, from drug eluting 
stents (Umashankar, Hari and Sreenivasan 2007). As discussed in the introduction to this 
thesis, a drug eluting stent is a device that releases a single or multiple bioactive agents 
into the bloodstream that affect the tissue adjacent to the stent. Currently there are three 
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different approaches to binding drugs to coronary stents: drug binding by means of a 
polymer on the stent surface, drug binding aided by an inorganic stent coating, or direct 
drug binding to the stent surface without coating (Acharya and Park 2006). Most often 
drugs are either chemically bonded to the surface of the stent or trapped within a polymer 
film or porous ceramic that allows controlled drug release (Kandzari, Tcheng and Zidar 
2002). Drug release in biodegradable coatings is achieved through disintegration of the 
biodegradable polymer of the stent, while non-biodegradable coatings release drugs by 
allowing the drugs to diffuse through a porous matrix. Whatever mechanism of drug 
binding used flow characteristics can have a significant influence on drug release and 
distribution within the tissue of the stented vessel (Neubert, et al. 2008). 
Currently, most preclinical drug elution studies consist of immersion of the drug 
eluting stent in a small volume of liquid, with drug concentration measurements taken 
over time or the use of computer generated computational models (Neubert, et al. 2008; 
Balakrishnan, et al. 2007; Alexis, et al. 2004). These methods allow for the examination 
of drug release but lack simulation of the vessel wall and cellular response and their 
possible influence on drug release and distribution. The examination of in vivo release 
and distribution is also limited since the drug concentrations in animals and humans 
cannot reliably be estimated due to low systemic blood concentrations and the fact that 
blood levels do not necessarily correspond to drug concentration at the stented lesion 
(Neubert, et al. 2008). Due to these limitations an in vitro model would be extremely 
valuable for the preclinical evaluation of drug elution kinetics. 
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The use of the in vitro BVM system developed in this thesis could provide a 
beneficial model for the study of drug elution kinetics. The BVM system provides an 
environment that could allow for observation and measurement of drug release and 
distribution within the vessel. With the addition of a cellular layer, the cellular response 
to drug concentrations in the blood and tissue could be better understood and a closed 
bioreactor system would permit precise drug concentration measurements at specific 
points in time. Drug concentrations in the BVM system could be easily measured in the 
circulating media, as well as in the media surrounding the scaffold, and in the scaffold 
and cellular layer itself. These types of measurements could provide important 
information on the influence of living tissue to drug release, distribution and local tissue 
affects which in turn could provide insight into the role of drug eluting stents on the 
cellular healing response and restenosis.  
 
Delivery Systems 
Much of this thesis has focused on the use of the BVM system to evaluate tissue 
response to implanted stents. However, as discussed in the introduction, in addition to the 
advancements in coronary stent design, the method of delivering these therapies has also 
improved. These improvements have made percutaneous coronary intervention 
procedures easier to perform and have reduced the amount of time for a single procedure. 
Percutaneous coronary intervention in complex coronary geometries is difficult 
and the increased complexity results in reduced success rates (Saeed, Banerjee and 
Brilakis 2008). Therefore, novel delivery systems, smaller catheters, lower profile 
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balloons and other devices have been created to overcome the challenges associated with 
tortuous anatomies. Stent delivery is an area of active research and a living model system 
for testing and evaluating these new delivery devices would be ideal for development and 
progression of the field.  
The future of the BVM system developed in this thesis has the potential to be 
used not only to evaluated tissue response to stent implantation but to the stent delivery 
processes and systems themselves. The BVM system could allow researchers to quickly 
evaluate the ability of the delivery system to safely and effectively implant a stent into a 
coronary vessel, with the advantage of observing tissue response to the delivery device, 
as well as the implanted stent. 
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The BVM Concept for Other Tissues 
Given the possible variability of the general BVM system concept, the following 
section will explore the potential to create chambers for the evaluation of medical devices 
in varying physiological tissue models. The BVM system developed in this thesis was 
designed to mimic coronary blood vessels and vascular tissue. However, the general 
concept can be used to model any tube like structure in which flow is present and has the 
potential to provide in vitro models of a wide variety of human tissues. 
 
Urology 
The ureter is a narrow muscular tube in which urine flows from the kidney to the 
bladder. A ureter may become obstructed as a result of a number of conditions including 
strictures, inflammation, cancer and kidney stones. When the ureter is obstructed, urine is 
unable to drain from the kidney and leads to pain, infection and if left untreated, kidney 
failure. Therefore, action must be taken to restore the flow of urine to the bladder.  
Ureteral stenting represents a minimally invasive procedure in which a ureteral 
stent, a small diameter plastic tube with pigtail shaped ends, is temporarily placed 
between the kidney and bladder to restore the flow of urine and provide a physical 
scaffold for the healing ureter. Ureteral stents have widespread use in current urological 
practice and are used for a wide variety of indications, the most common being the relief 
of urinary stone disease. Ureteral stents are used to maintain ureteral patency after 
endourological procedures and relive ureteral obstruction.  
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One significant complication associated with ureteral stent placement is 
encrustation within the stent lumen, blocking the flow of urine (Laube, et al. 2008; 
Tunney, Keane and Gorman 1997). Infection and pain are also common complications. 
As a result a number of new ureteral stent designs, materials, and coatings have been 
introduced to the market with the goal of preventing bacterial buildup and encrustation 
while increasing patient comfort (Kleinen, Böde and Laube 2008; Wignall, et al. 2008; 
Cadieux, et al. 2006; Hafron, et al. 2006).  
Several in vitro models have been developed for the preclinical testing of ureteral 
stents (Gorman, et al. 2003; Choong, Wood and Whitfield 2000; Stoller, et al. 2000). 
These models allow ureteral stents to be deployed and evaluated in anatomical 
geometries; however, no cellular lining exists to provide physiological response 
evaluations. Through the creation of an in vitro tissue engineered ureter construct a model 
system could be established for the initial testing of newly emerging urological 
technology. The need exists for new and advanced preclinical urological testing models 
that provide medical device manufacturers and researchers with the ability to quickly 
evaluate tissue response to new ureteral stent designs, materials and coatings.  
 
Abdominal Aortic Aneurysm 
Abdominal aortic aneurysm (AAA) is a common vascular disorder affecting 
approximately 5% of the male population over 55 years of age (Chong and How 2004). 
An abdominal aortic aneurysm occurs when a weak area of the abdominal aorta expands 
or bulges due to the high pressure of blood flowing through it. AAA is a significant 
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health risk since the aneurysm can burst or rupture at any time leading to severe bleeding, 
shock and death (Iribarren, et al. 2007). Therefore, action must be taken to ensure that if 
rupture or leakage occurs, blood flow through the abdominal aorta is not disrupted. 
Until recently, open surgical replacement of the diseased aortic segment with a 
prosthetic graft was the standard treatment for AAA (Steingruber, et al. 2006; Chong and 
How 2004). Endovascular aortic aneurysm repair (EVAR), however, has become an 
increasingly successful minimally invasive procedure for treating AAA. During EVAR 
an endovascular stent-graft is permanently placed within the abdominal aorta at the site 
of the aneurysm. The stent-graft provides a path for blood to flow through the aneurysm, 
reducing the pressure exerted on the weakened walls. 
There are significant complications associated with EVAR due to the high 
velocity flow and pressures present in the abdominal aorta. Complications include 
downstream migration of the stent-graft and leakage at the attachment site (Steingruber, 
et al. 2006). As a result development of the ideal endovascular stent-graft is ongoing and 
the need exists for an in vitro AAA flow model for evaluating endovascular fixation 
techniques, new stent-graft designs and materials, long term durability and the cellular 
response to these new technologies (Sulaiman, et al. 2008). Through the creation of an in 
vitro tissue engineered large diameter vessel construct a model system could be 
established for the initial testing of newly emerging AAA technology. 
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Potential as a Commercial Device 
The BVM systems developed in this thesis have the potential to be created on a 
large scale and sold to the biomedical industry as commercial preclinical testing devices. 
The BVM system could be marketed as an in vitro bench-top testing apparatus that 
mimics the human coronary artery environment. The BVM system could allow medical 
device manufacturers and researchers to conduct their own individual preclinical 
biocompatibility testing on a number of designs using a predictive model which could 
reduce the number of animal studies required. The Multipurpose BVM, especially, has 
the potential to be an ideal preclinical model since simple and complex vessel scaffolds 
can be accommodated allowing researchers to test devices in a number of vessel 
geometries. This type of preclinical testing may lead to better understanding of device 
and tissue interaction much earlier in the development process and give researchers the 
chance to make design improvements prior to animal and clinical studies.  
In order to market the BVM system as a commercial device, additional work 
would need to be completed. Extensive studies and comparisons would need to be made 
between the results obtained from the BVM system and animal models. Research would 
be needed to demonstrate that the BVM system provides predictive preclinical results that 
are comparable to those obtained from animal and clinical studies. Besides additional 
laboratory testing, ship testing would need to be performed to ensure that the BVM 
system can be transported without sustaining physical damage. In addition, testing would 
need to be conducted to ensure that the cells provided with the system are stored and 
packaged properly so that they survive shipment. Other considerations that would need to 
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be addressed include determining the number of times the system can be sterilized and 
reused prior to failure, the creation of detailed instructions for use, and large scale 
manufacturing ability. 
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Limitations and Future Work 
The in vitro tissue engineered blood vessel mimic (BVM) systems developed in 
this thesis and their feasibility for the initial testing of newly emerging intravascular 
technologies has been demonstrated. There are limitations that exist with these designs, 
however, and the focus of this section is to discuss the limitations of the current models 
and future improvements that can be implemented to improve their design. 
One design criteria that was not taken into consideration during the Ideal BVM 
development was the accommodation of physiological pressure and flow. The current 
BVM system setup uses low flow rates and low pressures. The performance of the Ideal 
BVM system has not been tested under high pressure, however, the thin compliant 
chamber walls may lead to failure. Under high pressure the walls may bellow, due to 
their flexibility, creating back pressure within the system. The ability of the lid to remain 
tightly sealed may also be compromised. Therefore, to improve the Ideal BVM system 
design it may be advantageous to use a container with more rigid walls that do not 
deform under high pressure. A stronger latching system may also be needed to prevent 
leakage from the lid. 
Although stent delivery and deployment were not performed in the Ideal BVM 
system designed in this thesis, the procedure remains identical to the original BVM 
system. Stent delivery and deployment is performed by inserting a balloon catheter 
mounted with a coronary stent into the bioreactor system through the luminal inlet. Flow 
is temporarily stopped during the deployment procedure and requires the luminal inlet to 
be disconnected from the bioreactor system. It would be advantageous if stent delivery 
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and deployment could be performed without disconnecting the BVM system and 
stopping flow. One way that this could be accomplished is by attaching a touhy borst 
adapter via a Y-connector to a section of tubing leading to the luminal inlet. A touhy 
borst adapter allows small diameter devices, such as balloon catheters, to be inserted 
through a small seal which prevents leakage at the insertion site. The addition of this 
feature could allow stent delivery and deployment to be performed without disrupting 
flow within the BVM system and represents a more realistic stenting procedure.  
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Conclusion 
As discussed in detail throughout this thesis, the blood vessel mimic system has 
the potential to help researchers predict the response of human tissue to intravascular 
devices prior to animal and clinical testing. The BVM system represents a more realistic 
and predictive model that could provide a high-throughput system for assessment of 
cellular response to novel intravascular technologies in order to direct animal and clinical 
studies toward the most promising devices. The benefits to medical device manufacturers 
and more importantly to patients needing these devices would be immense, resulting in 
better products reaching patients in a more timely fashion and at lower costs. With 
intravascular technologies advancing at a rapid pace, the BVM system has the potential to 
one day redefine how intravascular devices, specifically coronary stents, are tested and 
developed.  
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APPENDIX A: LIST OF ABBREVIATIONS 
 
AAA – Abdominal Aortic Aneurysm 
ACC – American College of Cardiology 
AHA – American Heart Association  
BMS – Bare Metal Stent 
BVM – Blood Vessel Mimic 
CABG – Coronary Artery Bypass Graft 
CAD – Coronary Artery Disease 
CHD – Coronary Heart Disease 
CT – Computerized Tomography 
DES – Drug Eluting Stent 
EC – Endothelial Cells 
ECG/EKG – Electrocardiogram 
ECHO – Echocardiogram 
EO – Ethylene Oxide  
ePTFE – Expanded Polytetrafluoroethylene 
EVAR – Endovascular Aortic Aneurysm Repair 
HA – Hyaluronic Acid 
HUASMC – Human Umbilical Artery Smooth Muscle Cells 
ID – Inner Diameter 
ISR – In-stent Restenosis 
IVUS – Intravascular Ultrasound 
MRI – Magnetic Resonance Imaging 
OD – Outer Diameter 
PBMA – Poly-n-butyl Methacrylate 
PC – Phosphorylcholine 
PCI – Percutaneous Coronary Intervention 
PCL – Polycaprolactone 
PDLA – Poly-D,L-lactic Acid 
PET – Positron Emission Tomography 
PEVA – Polyethylene-co-vinyl Acetate 
PGA – Polyglycolic Acid 
PLGA – Polylactic-co-glycolic Acid 
PLLA – Poly-L-lactic Acid  
P/N – Part Number 
PTCA – Percutaneous Transluminal Coronary Angioplasty 
SEM – Scanning Electron Microscope 
SMC – Smooth Muscle Cells 
TEBV – Tissue Engineered Blood Vessels 
VSMC – Vascular Smooth Muscle Cells 
W – Width 
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APPENDIX B: PART INFORMATION AND DRAWINGS 
 
Component Description Company Website Part Number  
Chamber 
Polypropylene Leak-
Proof Container, 
5"x4"x2", 350 ml 
Lock & 
Lock 
www.locknlock.com.au HPL806 
Chamber 
Polypropylene Leak-
Proof Container, 
8"x5"x2", 800 ml 
Lock & 
Lock 
www.locknlock.com.au HPL816 
 Buna-N  
O-Ring 
Soft Buna-N O-Ring 
AS568A Dash  
Number 006  
McMaster-
Carr 
www.mcmaster.com 2418T112 
Loctite 4011 
Loctite Prism 4011 
Medical Adhesive, 20 
Gram Bottle 
McMaster-
Carr 
www.mcmaster.com 1818A4 
Female Luer 
Lug Panel 
Mount-1/8" 
Barb 
Female Luer Lug Style 
Panel Mount 1/4-28 
UNF to 200 Series Barb, 
1/8" (3.2 mm) ID 
Tubing, White Nylon 
Value 
Plastics 
www.valueplastics.com FTLB230-1 
Lock Nut 
1/4-28 UNF Panel 
Mount Lock Nut,  
White Nylon 
Value 
Plastics 
www.valueplastics.com LNS-1 
Male Luer 
Lock-1/8" 
Barb 
Male Luer Integral Lock 
Ring to 200 Series Barb, 
1/8" (3.2 mm) ID 
Tubing, White Nylon 
Value 
Plastics 
www.valueplastics.com MTLL230-1  
Female Luer 
Thread-1/8" 
Barb 
Female Luer Thread 
Style to 200 Series Barb, 
1/8" (3.2 mm) ID 
Tubing, White Nylon   
Value 
Plastics 
www.valueplastics.com FTLL230-1  
Female Luer 
Thread-3/32" 
Barb 
Female Luer Thread 
Style to 200 Series Barb, 
3/32" (2.25 mm) ID 
Tubing, White Nylon   
Value 
Plastics 
www.valueplastics.com FTLL220-1  
Male-Female 
Coupler 
Male Luer Integral Lock 
Ring to Female Luer 
Thread Style Coupler, 
White Nylon   
Value 
Plastics 
www.valueplastics.com LC34-1 
Y-Connector-
1/8" Barbs 
Y-Connector with 200 
Series Barbs, 1/8" (3.2 
mm) ID Tubing,  
White Nylon 
Value 
Plastics 
www.valueplastics.com Y230-1 
1-Way 
Stopcock 
One-Way Stopcock, 
Capped Male Luer Lock 
to Capped Female Luer 
Thread Style, 
Polycarbonate Body w/ 
Polyethylene Handle 
Value 
Plastics 
www.valueplastics.com VP455980 
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3-Way 
Stopcock 
Three-Way Stopcock, 2 
Capped Female Luer 
Thread Style & Capped 
Male Luer Lock, 
Polycarbonate Body w/ 
Polyethylene Handle 
Value 
Plastics 
www.valueplastics.com VPB1000079N 
Male Plug 
Male Luer Integral Lock 
Ring Plug, Closed at 
Grip, White Nylon 
Value 
Plastics 
www.valueplastics.com LP4-1 
Male-to-Male 
Rotating Luer 
Male-to-Male Luer 
Connector with One 
Rotating Collar, ABS 
Qosina www.qosina.com 17664 
50 ml Tube 
BD Falcon™ 50 ml 
Conical-Bottom 
Polypropylene Tube 
BD 
Biosciences 
www.bdbiosciences.com 352098 
Silicone 
Tubing 
Tygon® Silicone Tubing 
1/8" ID x 1/4" OD 
Cole-Parmer www.coleparmer.com WU-95702-06 
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APPENDIX C: IDEAL BVM SYSTEM ASSEMBLY 
 
Component Company Part Number Quantity 
Leak-Proof Chamber Lock & Lock HPL806 1 EA 
Buna-N O-Ring McMaster-Carr 2418T112 6 EA 
Loctite 4011 Adhesive McMaster-Carr 1818A4 3 drops 
Female Luer Lug Panel Mount-1/8" Barb Value Plastics FTLB230-1 3 EA 
Lock Nut Value Plastics LNS-1 3 EA 
Male Luer Lock-1/8" Barb Value Plastics MTLL230-1 2 EA 
Female Luer Thread-1/8" Barb Value Plastics FTLL230-1  2 EA 
Y-Connector-1/8" Barbs Value Plastics Y230-1 1 EA 
Male-Female Coupler Value Plastics LC34-1 2 EA 
1-Way Stopcock Value Plastics VP455980 2 EA 
3-Way Stopcock Value Plastics VPB1000079N 1 EA 
Male-to-Male Rotating Luer Lock Qosina 17664 2 EA 
Tygon® Silicone Tubing, 1/8" ID Cole-Parmer WU-95702-06 11 inches 
 
1. Drill three 15/64" holes into the sides of the leak-proof chamber (Lock & Lock P/N 
HPL806). 
a. Drill the luminal inlet hole on the 
left face of the chamber 1 cm 
down from the top centered notch 
and 1 cm to the right. 
 
1 cm 
1 cm 
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b. Drill the luminal outlet hole on the right face of the chamber 1 cm down from 
the top centered notch and 1 cm to the left. 
c. Drill the extra luminal outlet hole on the right face of the chamber 1 cm down 
from the top centered notch and 2 cm to the right. 
 
2. Using a razor blade, remove any plastic 
debris that resulted from the use of the 
drill from the edges of the holes.  
 
 
 
3. Slide a Buna-N o-ring (McMaster-Carr P/N 2418T112) 
onto a female luer lug panel mount-1/8" barb (Value 
Plastics P/N FTLB230-1).  
 
1 cm 2 cm 
1 cm 
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4. Thread the female luer lug panel mount with the Buna-N o-ring through the drilled 
luminal inlet hole with the barbed portion exiting the side of the chamber.  
 
5. Slide a second Buna-N o-ring (McMaster-Carr P/N 2418T112) onto the barbed end of 
the female luer lug panel mount.  
 
6. Tightly screw a lock nut (Value Plastics P/N LNS-1) onto the female luer lug panel 
mount, pressing the o-rings against the inside and outside walls of the chamber. 
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7. Once securely tightened, place a drop of Loctite 
4011 adhesive (McMaster-Carr P/N 1818A4) 
between the lock nut and the threaded portion of 
the female luer lug panel mount. 
 
8. Repeat steps 3-7 for assembly of the luminal outlet 
and extra luminal outlet holes.  
 
9. Attach a 2" piece of Tygon® silicone tubing, 1/8" 
ID (Cole-Parmer P/N WU-95702-06) to the barbed 
fitting of the luminal inlet.  
 
10. Attach a female luer thread-1/8" ID barb (Value 
Plastics P/N FTLL230-1) to the open end of the 
silicone tubing attached to the luminal inlet. 
 
11. Secure the male luer lock end of a 3-way stopcock 
(Value Plastics P/N VPB1000079N) to the female 
luer thread attached to the silicone tubing. 
 
 
2" 
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12. Attach a 5" piece of Tygon® silicone 
tubing, 1/8" ID (Cole-Parmer P/N WU-
95702-06) to the barbed fitting of the 
extra luminal outlet. 
 
 
13. Attach a 1" piece of Tygon® silicone tubing, 1/8" ID 
(Cole-Parmer P/N WU-95702-06) to the barbed fitting 
of the luminal outlet. 
 
14. Attach a male luer lock-1/8" ID barb (Value Plastics 
P/N MTLL230-1) to the open end of the silicone 
tubing attached to the luminal outlet. 
 
15. Secure the female luer thread end of a 1-way 
stopcock (Value Plastics P/N VP455980) to the male 
luer lock attached to the silicone tubing. 
 
16. Attach a female luer thread-1/8" ID barb (Value 
Plastics P/N FTLL230-1) to the male luer lock end of 
the 1-way stopcock. 
 
5" 
1" 
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17. Attach a 2" piece of Tygon® silicone tubing, 
1/8" ID (Cole-Parmer P/N WU-95702-06) to the 
barbed fitting of the female luer thread attached 
to the 1-way stopcock. 
 
18. Insert the open ends of the silicone tubing 
attached to the luminal outlet and extra luminal 
outlet to a Y-connector with 1/8" ID barbs 
(Value Plastics P/N Y230-1). 
 
19. Attach a 1" piece of Tygon® silicone tubing, 
1/8" ID (Cole-Parmer P/N WU-95702-06) to the 
barbed fitting of the Y-connector. 
 
20. Attach a male luer lock-1/8" ID barb (Value 
Plastics P/N MTLL230-1) to the open end of the 
silicone tubing attached to the Y-connector. 
 
21. Secure the female luer thread end of a 1-way 
stopcock (Value Plastics P/N VP455980) to the 
male luer lock attached to the silicone tubing. 
 
2" 
1" 
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22. Place the lid with built in silicone o-ring on the assembled Ideal BVM chamber and 
close the four snapping latches. 
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APPENDIX D: TWO-PORT MEDIA RESERVOIR ASSEMBLY 
 
Component Company Part Number Quantity 
BD Falcon™ 50 ml Tube BD Biosciences 352098 1 EA 
Buna-N O-Ring McMaster-Carr 2418T112 4 EA 
Loctite 4011 Adhesive McMaster-Carr 1818A4 2 drops 
Female Luer Lug Panel Mount-1/8" Barb Value Plastics FTLB230-1 2 EA 
Lock Nut Value Plastics LNS-1 2 EA 
Male Luer Lock-1/8" Barb Value Plastics MTLL230-1 2 EA 
Female Luer Thread-1/8" Barb Value Plastics FTLL230-1  1 EA 
Tygon® Silicone Tubing, 1/8" ID Cole-Parmer WU-95702-06 21 inches 
 
 
1. Drill two 15/64" holes into the lid of a BD Falcon™ 50 
ml tube (BD Biosciences P/N 352098). 
 
2. Using a razor blade, remove any plastic debris that 
resulted from the use of the drill from the edges of the holes.  
 
3. Slide a Buna-N o-ring (McMaster-Carr P/N 2418T112) 
onto a female luer lug panel mount-1/8" barb (Value 
Plastics P/N FTLB230-1).  
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4. Thread the female luer lug panel mount with the Buna-
N o-ring through one of the drilled holes with the 
barbed portion exiting the top of the lid. 
 
 
5. Slide a second Buna-N o-ring (McMaster-Carr P/N 
2418T112) onto the barbed end of the female luer lug 
panel mount.  
 
6. Tightly screw a lock nut (Value Plastics P/N LNS-1) 
onto the female luer lug panel mount, pressing the o-
rings against the top and bottom of the lid. 
 
7. Once securely tightened, place a drop of Loctite 4011 
adhesive (McMaster-Carr P/N 1818A4) between the 
lock nut and the threaded portion of the female luer lug 
panel mount. 
 
8. Repeat steps 3-7 for assembly of the second hole.  
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9. Attach a 1" piece of Tygon® silicone tubing, 1/8" ID 
(Cole-Parmer P/N WU-95702-06) to a male luer lock-
1/8" ID barb (Value Plastics P/N MTLL230-1). 
 
 
 
10.  Secure the male luer lock fitting of the silicone tubing 
assembly to one of the female luer lug panel mounts 
exiting the bottom of the lid. 
 
 
11. Attach two 10" pieces of Tygon® silicone tubing, 1/8" 
ID (Cole-Parmer P/N WU-95702-06) to the barbed ends 
of the female luer lug panel mounts exiting the top of the 
lid. 
 
 
 
 
 
 
 
1" 
10" 
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12. Attach a male luer lock-1/8" ID barb (Value Plastics P/N 
MTLL230-1) to the open end of the silicone tubing attached 
to the female luer lug panel mount with the 1" silicone tubing 
assembly. 
 
 
 
 
 
 
 
13. Attach a female luer thread-1/8" ID barb (Value Plastics P/N 
FTLL230-1) to the open end of the silicone tubing attached 
to the other female luer lug panel mount. 
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14. Screw the bottom section of the BD Falcon™ 50 ml tube to the assembled two-
port media reservoir lid. 
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APPENDIX E: SCAFFOLD LENGTH VS NUMBER OF COUPLERS USED 
 
Illustration # of Couplers Scaffold Length 
 
0 5.5 cm 
 
1 4.5 cm 
 
2 3.5 cm 
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APPENDIX F: BVM SYSTEM USER FEEDBACK SURVEY 
 
Name: _________________________ 
Date: __________________________ 
 
1. Overall Usability    Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
 
2. Setup      Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
 
3. Scaffold Assembly     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM  1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
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4. Scaffold Insertion     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
5. Media Injection     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
6. Seal-ability      Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
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7. Aseptic Use      Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
8. Bioreactor Assembly     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
9. Control of Flow    Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
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10. Adjustability     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
11. Components and Fittings   Awkward       Convenient 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
12. Component Configuration   Poor                      Excellent 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
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Dimitri Delagrammaticas 
 
still need a non-sterile partner but fittings and lid make overall use 
easier 
 
 
separation of lid from chamber makes setup easier; male and female 
fittings ensure correct setup; no air bubbles; no tools needed 
 
no difference between old and new BVM; scaffold setup is easy  
 
07/01/08 
BVM SYSTEM USER FEEDBACK SURVEY 
 
Name: _________________________ 
Date: __________________________ 
 
1. Overall Usability    Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
 
2. Setup      Difficult   Easy 
 Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
 
3. Scaffold Assembly     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
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lid does not have to be held freeing up an extra hand for use; rotating 
luer lock fittings make insertion very easy  
 
media injection is the same for both systems through the three-way 
stopcock; air bubbles are easier to eliminate from new chamber but 
new chamber requires more media  
 
built-in o-ring seal is nice; lid is easy to snap to chamber and creates a strong 
leak-proof seal; no tools needed when snapping on lid 
 
4. Scaffold Insertion     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
5. Media Injection     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
6. Seal-ability      Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
 Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
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separating the lid from the chamber improves aseptic use; lid can be 
sterilized individually 
 
only one way to connect chamber to media reservoir; fast and easy 
but new chamber is larger 
 
stopcocks are easier to use than side clamps and firmly block flow; 
placement of one-way stopcocks makes control of flow easy 
 
7. Aseptic Use      Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
8. Bioreactor Assembly     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
9. Control of Flow    Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
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one-way connections to reservoir eliminates the confusion on which 
end to connect when assembling the complete bioreactor system; 
connection piece used in media reservoir sterilization is eliminated 
 
elimination of UV glue improves component setup; components and 
fittings are simple to use 
 
adjustability is limited to couplers; adjusting with couplers is easy and 
provides consistent scaffold lengths 
 
10. Adjustability     Difficult   Easy 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
11. Components and Fittings   Awkward       Convenient 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
 
12. Component Configuration   Poor                      Excellent 
Original BVM    1  2 3 4 5 
Ideal BVM    1  2 3 4 5 
 
Comments: 
____________________________________________________________
____________________________________________________________ 
____________________________________________________________ 
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APPENDIX G: REPRINT PERMISSIONS 
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